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ABSTRACT OF DISSERTATION 
 
CELL SURFACE COATINGS FOR MAMMALIAN CELL-BASED THERAPEUTIC 
DELIVERY 
 
The cell plasma membrane is an interactive interface playing an important role in 
regulating cell-to-cell, cell-to-tissue contact, and cell-to-environment responses. This 
environment-responsive phospholipid layer consisting of multiple dynamically balanced 
macromolecules, such as membrane proteins, carbohydrate and lipids, is regarded as a 
promising platform for various surface engineering strategies. Through different chemical 
modification routes, we are able to incorporate various artificial materials into the cell 
surface for biomedical applications in small molecule and cellular therapeutics.     
In this dissertation, we establish two different cell coating techniques for 
applications of cell-mediated drug delivery and the localization of cell-based therapies to 
specific tissues. The first part of this dissertation establishes a membrane-associated 
hydrogel patch for drug delivery. The crosslinking of a grafted polymeric patch from a 
mammalian cell membrane is achieved through surface-mediated photolithographic 
polymerization. With the use of photomask, the formation of nanoparticle-loaded 
PEGDA hydrogel is controlled to deposit various geometric features on photoinitiator-
immobilized surfaces. Through microarray patch patterning, we analyzed the influence of 
processing parameters on the accuracy of polymer patterning on a microarray. We then 
optimized the patterning approach for the formation of PEGDA patches on live A549 
cells.  
In the second part of this dissertation, we study the use of tissue-adhesive coatings 
to improve the retention of therapeutic mesenchymal stem cells (MSCs) in the heart 
following intramyocardial or intravenous injection. MSCs were coated with antibodies 
against ICAM1 to adhere to CAM-overexpressed endothelium present in the heart 
following MI. Through intramyocardial or intravenous delivery, we observe higher 
number of coated cells retained in the heart over uncoated ones, supporting enhanced 
affinity for the inflamed endothelium near the infarct. We correlate the detachment force 
of antigen-interacted MSCs by a parallel laminar flow assay with the density of ICAM on 
the substrate and the density of anti-ICAM on the MSC surface. MSC retention on CAM-
modified surfaces or activated HUVECs was significantly increased on antibody-coated 
groups (~90%) under physiologically hemodynamic forces (< 30dyne/cm2), compared to 
uncoated MSCs (~20%). Moreover, a dramatic reduction of immune cell quantity was 
observed after intravenous injection, indicating the enhanced immunoregulatory efficacy 
by systemically delivering ICAM-adhesive MSCs to the site of inflammation. 
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CHAPTER 1. TECHNIQUES FOR COATING MAMMALIAN CELLS 
1.1 Introduction: roles of cell surface engineering  
Cell membrane is a complex phospholipid bilayer covered by a variety of biological 
components including glycolipids, proteins and carbohydrate chains. This biointeractive 
interface not only acts as a safeguard against unwanted intruders but also governs the 
communication and essential nutrient exchanges between inner and outer region of a cell. 
Given diverse biological moieties displayed on the surfaces of different cell types, 
engineering the surface of a cell provides huge potentials to transform the intrinsic 
functions and activities of cell surface components to match specific therapeutic targets or 
biomedical needs.  
Cell surfaces are composed of diverse biochemical and are characterized to achieve 
exclusive functions through both genetic and non-genetic techniques. Recently, the first 
therapy based on the genetic modification of a cell surface was approved by the FDA, and 
the delivery of chimeric antigen receptor-modified (CAR) T-cells is now used clinically 
for blood cancers such as leukemia and melanoma. T cells are collected from a patient’s 
blood are genetically reprogrammed by gene sequence insertion using inactive viral 
vectors. The genetic manipulation enables reprogramming of T cell surface structure by 
expressing tumor antigen-recognized CAR for targeting cancer cell antigen [1].  
However, challenges of genetic cell surface manipulation remain [2]. Firstly,  
genetic modification methods do not really induce the expression of desired substances, 
limiting the coating choices on cells. Secondly, genetic manipulation is subject to low 
transfection efficiencies, where the fraction of cells showing any significant change in 
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properties is significantly less than one. Beyond the efficiency, the genetically-engineered 
cells require time for transcription and protein synthesis, requiring hours to days for 
surface modification. Finally, there are still significant concerns over the safety of viral 
transfection approaches, and modern non-viral methods lag behind viral methods in 
transfection efficiency and cell toxicity. As a result, this dissertation broadly focuses on 
non-genetic strategies for cell surface modification of functional mammalian cells. Cell 
surface coating can perform unique biological functionalities that cells inherently lack. In 
our work, the engineered cells are capable of carrying drug payload for cell mediated drug 
delivery or selectively targeting tissues of interest for local cell retention in the heart, while 
maintaining their intrinsic cellular properties to interact with extracellular environment. 
Here, we describe the current strategies for non-genetic cell surface engineering. They are 
broadly divided into covalent and non-covalent approaches, and this chapter contrasts the 
strengths and weaknesses of each approach. 
1.2 Current non-genetic cell surface engineering technologies: non-covalent 
interaction 
To alter the intrinsic functionalities of cell surfaces by non-genetic methods, non-
covalent and covalent bonds are two main categories of molecular binding and are widely 
used to attach biomaterial coatings on cell surfaces (Figure 1.1). Non-covalent binding 
includes electrostatic interactions, hydrogen bonds, ionic bonds and van der Waals 
interactions, and has relatively weak binding energy which can possibly be broken by 
molecule activities at physiological conditions; however, noncovalent interactions are still 
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considered as critical modification processes to regulate cell surface protein-protein 
interactions and cell membrane dynamics. 
1.2.1 Cell surface coating through electrostatic interactions  
The extracellular composition of glycoprotein and glycolipid residues on a cell 
membrane exposes negative ions provided from oligosaccharides, driving the cell plasma 
membrane to be a negatively charged interface that electrostatically attracts essential 
cations for normal cellular functions. For cell surface coating, the peripheral membrane’s 
negative charge can be regarded as an adhesive surface for non-covalent deposition of 
positively charged materials, such as polycationic peptides, proteins, polymers or 
nanoparticles (Figure 1.2).  
Notably, the fabrication of polyionic polymers through layer-by-layer (LbL) 
techniques offers a direct method for creating a cytoprotective coating. Through sequential 
deposition of oppositely charged polyelectrolyte layers, a multilayer polymer thin film is 
directly form on the surface of each individual cell. From Tabrizian’s lab, alternative 
coating of anionic AL and cationic PLL polyelectrolyte on red blood cells (RBC) generated 
universal RBCs that are not immunologically recognized by immunotargeting [3]. This 
multilayer encapsulation on RBCs protected cells from antibody-A capture and showed no 
aggregation caused by immunorecognition after introducing antibody-A, supporting a 
strong reduction in immunogenicity and antigenicity of blood group antigens. 
Additionally, coated cells maintained their oxygen carrying capacity and also released 
amounts of ATP and hemoglobin consistent with the low levels of cell death of seen in 
uncoated cells [3]. Similarly, absorption of polycationic PEI mixed with silica 
nanoparticles, considered as an artificially protective cell wall, on negatively charged 
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mammalian cell membrane (HeLa, NIH 3T3 fibroblast and Jurkat) demonstrated coating-
based cytoprotection from enzyme-induced cell apoptosis [4]. Another group has exploited 
LbL deposition of PLL(+)/HA(-) nanolayers to form a protective coating on mesenchymal 
stem cell (MSC) cell membrane without affecting cell morphology, showing the material 
absorption potential on MSCs through electrostatic attraction. However, the long term 
viability of PLL-encapsulated MSCs began to decrease after several days [5].  
While most studies utilize polyelectrolyte materials like PLL [3, 5], PAH [6, 7] and 
PEI [4], Germain M et al. have proposed PDADMAC/PSS as a more biocompatible LbL 
polymer coating on MELN breast cancer cells. The cell-associated PDADMAC coating 
showed three-fold higher on cell viability than the use of PLL, PAH and PEI.  In addition, 
PDADMAC-coated cells demonstrated cytoprotection from macromolecular by 
prohibiting the internalization of 60kDa and 80kDa proteins [8].  
In all, electrostatic deposition of polymeric materials provides a simple and rapid 
method for coating the charged surface of a cell [6, 7, 9, 10]. While the coating of 
polycation polymer can protect cells from unfavorable molecule invasion, the charged 
covering that is always destructive for cells could certainly compromise the fragile nature 
of mammalian cell membrane, limiting its use for long-term cell activities.  
1.2.2 Cell surface coating through hydrophobic lipid interactions  
Lipids are broadly used materials for protein conjugation and drug delivery due to 
their biocompatibility and controllable structural properties for a variety of 
bioconjugations. Here, they are considered as a cell surface coating material to conjugate 
specific bioactive molecules on the surface of living cells for specific targeting purposes. 
Due to poor water solubility of lipid tail, PEGylation is widely employed to create 
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amphiphilic PEG-derivative lipids for cell plasma membrane modification. Namagune’s 
group [11] demonstrated the stable grafting of single lipid tailed oleyl‐PEG-biotin or 
double lipid tailed-DOPE‐PEG-FITC on surfaces of human and sheep erythrocytes. 
Because of the coverage of lipid tails anchored onto plasma membranes, DOPE-modified 
cells showed the great antigen masking efficiency to escape from the recognition of 
antibody against A antigen on erythrocytes.   
Moreover, the uses of protein-conjugated lipids to incorporate non-naturally and 
non-abundantly expressed proteins on MSC surfaces were exhibited by Bull’s group. 
Varying molecular weights of PEG groups were used to support [12, 13] the high viability 
of coated MSCs after phospholipid modification. MSCs were designed for targeting 
specific MSC homing factors using lipid-PEG conjugates with terminal targeting groups. 
Ligand protein SDF-1 and its cognate receptor CXCR4 are known as MSC recruiting 
factors, and these were conjugated on the distinct functionalized ends of two different 
PEGylated DMPE lipid using NHS [13] or maleimide [12] conjugation. The surface-
coating of CXCR4 or SDF-1 enhanced the MSC migration toward its corresponding 
homing target to support the potential CXCR4/SDF1-directed MSC recruitment into 
ischemic myocardium by this protein-phospholipid cell surface coating. In addition, 
homing peptide CRPPR-grafted phospholipid (DMPE-PEG-CRPPR), conjugated through 
the reaction between lipid-maleimide and cysteine-containing peptide, was also 
hydrophobically embedded onto MSC surfaces. It indicated that by increasing the amount 
of intercalated homing peptide, the number of coated MSCs that migrated to the gradient 
of target protein CRIP2 also increased [13].   
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Other than synthetic lipid domains like DMPE or DOPE, multiple studies have 
showed the use of naturally-derived lipid products to hydrophobically decorate cell 
surfaces. PEGylated glycol chitosan-cholesterol-biotin was intercalated into the surface of 
A549 cells and labeled with a fluorescent streptavidin for cell imaging up to 8 hours [14]. 
The two-step biotinylation via click chemistry was processed by inserting the DBCO 
(dibenzocyclooctyne)-labelled cholesterol and DSPE onto RAW 247 macrophage cell 
membrane. The cholesterol-anchored cell surfaces gave a greater biotinylation reactivity 
than the DSPE phospholipid biotin; moreover, both synthetic and naturally-derived lipid 
anchorage exhibited negligible cytotoxic effects on lipid-modified cells [15]. 
Palmitate acid is another naturally formed saturated fatty acid and is known as its 
importance of protein lipidation and localization on cell plasma membranes. Early study 
from Peacock’s group has first established the conjugation of antibody with NHS-
derivative palmitate acid for one step cell surface antibody decoration. The pre-conjugated 
antibody-palmitate was hydrophobically intercalated into the membrane of P388D1 cells. 
Interestingly, it was found that P388D1 macrophages bearing artificial receptor (anti-
CRBC) was able to interact with CRBC cells to enhance cell-cell interaction [16]. The 
advantage of hydrophobic lipid-anchorage on cell membrane modification is that non-
permanent lipid insertion preserves intrinsic protein properties on plasma membrane and 
has less harmful effects on cellular functions. However, the retention of cell surface-
intercalated lipids might decrease over time due to their weak binding. The irreversible 
and transient kinetics of lipid-membrane interaction could be simply interfered by the 
dynamically fluctuated phospholipid interface. Additionally, lipid breakdown could cause 
instability of cell surface structure. The presence of multiple lipid enzymes, in an 
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extracellular microenvironment, could naturally digest lipid chains into smaller pieces, 
leading to functionality loss of lipidated bioconjugate. 
1.2.3 Cell surface coating through antibody-antigen specificity 
Every cell population has its unique profile of cell surface markers, allowing 
antibody-antigen affinity to drive adhesion to the surface of targeted cells. This targeted 
adhesion creates opportunities for specific or nonspecific coupling of ligands to the cell 
surface. Most commonly, NHS-ester groups are used to tether biotin [17], horseradish 
peroxidase (HRP) [18, 19], magnetic beads [20], nanoparticles [21, 22] and a variety of 
fluorophores to antibodies,  and this diversity expands the portfolio of potential biological 
applications in cell surface coating. 
Our lab uses antibody-antigen specificity to purify cells based on marker-
expression through antigen-specific lysis [23-25]. An ultrathin hydrogel coating was 
grafted from the membrane of antigen positive cells by surface-initiated 
photopolymerization. A biotinylated antibody was specifically adhered to antigen-positive 
cells in order to support immobilization of a streptavidin-photoinitiator, and crosslinked 
coatings were generated through the surfaces of antibody/photoinitiator-conjugated Jurkat 
or A549 cells under visible light irradiation. These hydrogel coatings form and protect 
only antigen-positive cells from lysis conditions by surfactants or hypotonic solutions. A 
similar antigen specific cell coating was reported by Sakai et al to encapsulate antigen 
positive cells by enzyme-mediated polymerization [26]. Horseradish peroxidase is a 
protein enzyme commonly used to catalytically label antigens in immunohistochemical 
staining and ELISAs. HRP is a potent activator  for radical polymerization of vinyl 
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monomers or aromatic derivatives [27, 28], and HRP was used in this study to selectively 
form alginate hydrogel coatings on CD31+ and CD326+ cells [26]. 
Because antibodies have unique antigen-binding domains to target specific cell 
surface markers, researchers have come up with a coating of bispecific antibody on cells 
by creating a hybrid combination of two different antibodies. This antibody-fused material 
with dual antigen-interacting parts was used to coat the cytotoxic killer cells for cancer 
cell targeting. Early work in 1990, Taizo Nitta et al. designed a heterofunctional 
monoclonal hybrid that has both CD3 (T cells) and LU246 (glioma cells) targeting 
properties by fusing two different SH-reduced antigen-binding fragment (Fab) into one 
asymmetric antibody structure. Effectively, the coating of glioma-recognized antibody 
hybrid on T effecter cells exhibited the enhanced cytotoxic targeting in glioma cells than 
the ones without this immunoconjugate [29]. Additionally, the coating of bispecific 
immunostructure on T lymphocyte [30] or cytokine-induced killer cells [31] has showed 
improved tumor cell targeting efficacy through different designs of antigen binding 
orientation [30, 31]. The dual functional antibody with both CD3 and CD123 recognized 
variable domains was used to coat CD3+ effector T lymphocyte. The delivery of T cell-
conjugated bispecific antibody that has CD123 targeting ability was successfully proved 
to effectively eliminate CD123+ leukemia tumor cells [30].  
The high selectivity of antibody anchoring presents a significant advantage over 
other coating grafting techniques. Critically, there are also several limitations with 
antibody supported coatings. Selecting an adequate cell surface marker for coating only 
on a target cell could be a tricky issue because 1) the same cell surface proteins might be 
expressed on distinct cell lineages and 2) the large variability in expression levels within 
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a single population of cells. In many cases, the antigen’s density is too low to effectively 
modification the cell’s surface [23]. Moreover, antibody labeling some surface receptors 
will trigger intracellular signaling [32-34] that could lead to unexpected cellular activities.    
1.2.4 Cell surface coating through receptor-ligand interactions 
Cell surface receptors are specialized transmembrane cellular proteins with unique 
tertiary structures that specially respond to corresponding docking ligands. To date, 
approaches using ligand-receptor binding affinity has been increasingly investigated in 
cell surface modification for specialized cell-responsive interactions. For example, the 
binding between hyaluronic acid (HA) ligand and its receptor CD44 is one of the key 
regulatory interactions for coating deposition [35]. The inflammatory CD44 upregulation 
drives the membranes of immune cells, such as leukocyte, macrophage or monocyte, as 
HA-targeted interfaces for the surface loading of polymer drug payload or backpack for 
cell-mediated drug delivery and uptake [35, 36].  
A multilayer polymer-fabricated backpack loaded with a CD44-adhesive HA 
interface was specifically attached to the CD44-expressed leukocyte [37] or macrophage 
[38] for long-term based drug carrying. By precisely controlling the material size, 
geometry [39] and orientation [40], the coating through this HA-CD44 interaction allowed 
the sustaining loading only on living CD44+ leucocytes and lymphocyte B cells with no 
further material engulfment. This surface-attached polymeric film was known to increase 
cell-cell interaction and communication. The events of cell aggregation were raised in 
response to the increase in surface area of CD44 contacting backpacks [39]. Similarly, the 
modification of Fe3O4 nanoparticle-loaded backpack through HA-CD44 interaction was 
also applied to magnetically control the migration of backpack-adhered B cells [37]. These 
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coating examples through ligand-receptor affinity provides a stable surface loading 
strategy for cytotoxic killer cells to deliver the drug payload.   
While ligand-receptor interaction also offers some cell-targeting specificity, the 
opportunity for inadvertent activation requires caution with this approach. Surface binding 
on receptor could accelerate internalization of the surface coated materials and decrease 
the availability of the surface-loaded materials. Thus, while there are opportunities for 
receptor ligand anchoring, the potential for unintended biological responses often 
outweigh the benefits of this strategy. 
1.2.5 Cell surface engineering through covalent amide bonds 
Covalent attachment provides a more stable attachment then noncovalent strategies 
through the formation of an irreversible binding to the cell surface. The cell’s peripheral 
membrane is composed of numerous structures for covalent binding, including proteins, 
phospholipids, and carbohydrate chains. In this dissertation, I commonly conjugate groups 
to the cell surface covalently through the formation of an amide bond on cell surface 
proteins.  
Owing to the hydrophilic nature of amine groups, lysine residues are typically 
presented at the external surface of protein, and these residues are convenient for chemical 
modification. In this section, we focus on different types of amine-reactive chemistries 
used for biomaterial attachment in a physiological environment. One amine crosslinking 
strategy is to covalently link cyanuric chloride on cell surface glycoproteins. Blackall  et 
al. used PEGylated cyanuric chloride to form a PEGylated layer around proteins on red 
blood cell to camouflage the cells from parasite invasion and immune recognition [41]. 
Unfortunately, potential cytotoxicity after surface modification with cyanuric chloride 
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limits this covalent binding for cell surface engineering beyond the relatively stable red 
blood cells.  
NHS ester linker are frequently used to decorate living mammalian cells by forming 
stable covalent amide-bonds in mild and slightly alkaline biological conditions (pH 7-8) 
[12, 23, 42-47]. In contrast to long metabolic engineering processes for covalent binding, 
NHS covalently binds structures to cells in under an hour. This approach has been used to 
rapidly tether NHS-DNA ligands to the surface of multiple mammalian cell types, 
including T cells, red blood cells and cardiac myoblasts without affecting their intrinsic 
cellular phenotypes. These specific cell coatings were then used to rapidly adhere cells to 
complementary DNA patterned on a glass surface [42]. Sulfonated NHS derivatives have 
increased water solubility and improve biocompatibility for cell surface modification, and 
this strategy is used to tether protein-signaling aptamers [43] or biotin [44-46] to the 
surfaces of MSCs.  
Covalent biotinylation strategy using sulfonated NHS-LC-biotin was also utilized 
by Karp’s group to coat biotinylated SLex ligand on MSCs for mimicking leukocyte 
extravasation through endothelium. With ligand coating, Karp et al. observed the reduction 
of MSC rolling velocity on P-selectin modified surface [44] and the increased MSC 
homing to inflamed ear in an inflammation-induced murine model after in vivo vein 
injection [45], in contrast to unmodified cells. For drug delivery applications, another 
study from Anderson’s lab also employed NHS-ester biotin to load neutravidin 
nanoparticles on human mesenchymal stem cells (hMSCs) without changing their 
tumoritropic property [46]. 
12 
 
The sulfo-NHS biotin strategy is particularly useful as an adaptable tool for 
additional cell surface functionalization. Of particular relevance, our lab demonstrated a 
cell encapsulation technique by covalent NHS ester biotinylation [23, 47]. Grafting of the 
streptavidin-conjugated photoinititator to a biotinylated cell interface rapidly facilitated 
polymerization around individual living cells, allowing the generation of polymer coating 
for different application such as cytoprotection [23] or tissue targeting [47].  
1.3 Surface-mediated polymerization on individual cells 
Building hydrogel thin film through surface initiation provides a great foresight in 
surface engraftment of polymeric materials (Figure 1.2). Prior study about individual cell 
polymerization has grafted nano-thin polymers on yeast cells by surface-activated ATRP 
polymerization to exhibit cytoprotective effects. While this uniformly formed polymer 
coating can prevent cell agglutination during E-coli introduction [48], the non-
physiological operating conditions of ATRP system and the demand of transition metal 
catalyst CuBr2 could lead to lethal DNA cleavage through the oxidative activation, making 
it not suitable for mammalian cell manipulation. Various works in thin film generation 
have established the local grafting of acrylate or methacrylic polymer on a photoinitiator-
immobilized surface through radical propagation [49-54].  Previously, Seda Kızılel et al. 
designed an eosin-initiated photografting system in combination with co-initiator 
triethanolamine (TEA) and accelerator vinyl pyrollidinone (VP) to rapidly form a 
polyethylene (glycol) diacrylate (PEGDA) hydrogel film on an eosin-localized surface. By 
introducing photon energy from visible light, the excited eosin in triplet state promotes the 
formation of eosin radical and a cation TEA radical that is critical for polymer propagation 
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by cleaving acrylate double bond [50]. This eosin-based photocrosslinking system further 
provided a significant approach to greatly establish polymer-based amplification for 
multiple biological application, such as biodetection assay [51, 52], surface encapsulation 
or coating on proteins, living cells or tissues.  
Our group has developed the generation of polymerized coating on an eosin-
immobilized cell surface (Figure 1.3). Previously, we has demonstrated an antigen-targeted 
polymer coating on eosin-localized fixed fibroblast, suggesting the feasibility to create a 
dye-loaded film for protein signal amplification on each single cell [55]. This surface free 
radical polymerization consisting of PEGDA, TEA and VP was further developed to 
deposit an ultrathin hydrogel film on living mammalian cell encapsulation for different 
biological purposes. We also examined the feasibility of surface-coated gels to protect 
cells from immunoattack by evaluating the transport behavior of dextran particles with 
different molecular weights through the antigen-based polymer coating on individual 
Jurkat cells. Biotinylated antibody recognition on CD45-expressed Jurkats allowed surface 
localization of SAEITC to specifically photocrosslink the PEGDA hydrogel on the living 
cell membrane. The results from diffusion assay interpreted that either PEGDA575 or 
PEGDA3500 showed complete molecule exclusion of dextran particles with molecular 
weight higher than 10kDa, suggesting the ability of PEGDA-coated cells to effectively 
reject the immune attack by host antibody [25].  
Through this size-dependent exclusion property, a degradable coating of PEG 
acrylate monomer was utilized to design an antigen-selective cell sorting system through 
antigen-specific lysis (ASL). The coating can protect antigen-positive cells from SDS 
surfactant lysis. By specially targeting EpCAM-positive A549 or CD45-positive Jurkat, 
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targeted cells can be collected in high purity (over 90%) and maintain their biological 
functions after coating removal [24]. To thoroughly understand the coating efficacy by this 
surface-initiated polymerization method, the yields of intact cells using both amine-
conjugated and antigen-conjugated biotinylation were investigated after SDS lysing 
depletion. The cells modified through covalent amine-reacted biotinylation provided at 
least ten-fold higher eosin density than antibody-tagged cells, resulting in much higher 
yield (20%) than others (1% for antibody-labeled cells and 0.1% for untreated cells). This 
evidence clearly showed the role of surface-conjugated eosin is highly dependent on the 
polymerization efficiency for this cytoprotective coating [23]. In addition to eosin, 
fluorescein appears to be an alternative surface-conjugated photoinitiator in this 
photopolymerization coating system. Our lab previously established the PEGDA3500 
coating on living A549s through SAEITC-based or FITC/antibody-based 
photopolymerization. Both coating approaches successfully present the cell protection 
property under hypotonic conditions [56]. Other than cytoprotective applications, recent 
work from us also used surface-polymerized cells to improve stem cell retention following 
myocardial infacrtion. A synthetic acrylate gelatin polymer which provides extracellular 
tissue adhesion property was generated on the bone marrow cell surface. It was proved 
that by creating this gelatin coating, we were able to enhance in vivo cell localization in 
the infarcted heart tissues [47]. Importantly, in this dissertation, we will take advantage of 
this surface-polymerized operation to create a membrane coating with specific 




Figure 1-1. Common methods of anchoring coating to a mammalian cell surface. 
















Figure 1-2. Material systems for coatings on mammalian cell surfaces. Reprinted from 






Figure 1-3. The generation of polymer coating on living cell surface through surface-




CHAPTER 2. CELL SURFACE COATING DESIGNED FOR DRUG DELIVERY 
2.1 Introduction 
The human body is a complex bioreactor where an intricate chemical balance is 
maintained through passive and active transport. Modern drug delivery systems have been 
successful in leveraging our passive transport mechanisms to deliver drugs through the 
airways, circulatory system, and diverse tissues. Only recently has the research community 
started to utilize the active transport mechanisms for cell-directed transport of species in 
the body. Cell-mediated delivery is a revolutionary approach to exploiting natural cell 
behaviors, which include migration across biological barriers and targeted homing to 
tumors or sites of inflammation [58-61]. Cellular coatings are emerging as a promising 
approach for the delivery of a therapeutic payload to a specific site. Therapeutic cargo is 
attached to the plasma membrane of tissue-targeting transporter cells to enhance site-
specific delivery. Here, the chapter highlight the opportunities enabled by the recent 
clinical and preclinical studies which coated transporter cells are being used for drug 
delivery applications. 
This section will focus on designing cell coatings for the specific applications in 
drug delivery. The following content presents a minor adjustment of our previously 
published review article on the journal of biological engineering. 
Kara A. Davis,# Pei-Jung Wu,# Calvin F. Cahall, Cong Li, Anuhya Gottipati, and Brad 
J. Berron. Coatings on mammalian cells: interfacing cells with their environment. 




2.2 Coating designed to modulate the immune system 
In many autoimmune diseases, immune cells mistakenly identify beneficial cells as 
a harmful species, resulting in chronic inflammation. In the case of multiple sclerosis 
(MS), cellular coatings have been designed to introduce immunologically-active 
substances, preventing the immune cells from attacking the normal nerve cells near the 
site of the brain and spinal cord [62]. A recent clinical study demonstrated the feasibility 
of antigen-specific tolerance therapy by intravenously transporting antigen-mimicking 
cells to T cell [63]. For MS, autologous peripheral blood mononuclear cells are coated 
with myelin antigens are used to stimulate antigen tolerance through interaction with 
myelin-specific T cells. For early stage patients treated with myelin coated cells, the vital 
signs and the blood cell composition of the patients were stable and no relapse occurred 
within 3 months of treatment.  
Similar cell coatings were designed to target and deplete the specific T cell 
populations responsible for diabetic injury [64]. ERY1 peptide linkers were used to coat 
the surface of erythrocytes with a foreign ovalbumin species. Following intravenous 
injection, ovalbumin-coated erythrocytes were disproportionately targeted by the dendritic 
cells capable of indirect antigen specific tolerance. By also incorporating immune-induced 
antigens onto the surface of these erythrocytes, the cells promoted targeted depletion of 
the CD4 and CD8+ T cells. These findings were further supported with a type I diabetic 
mouse model, where antigen-engineered erythrocytes induced clonal depletion of T cells, 
and the expression of IFN-γ-positive T cells was significantly reduced over ovalbumin-
negative controls and ovalbumin alone. 
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Multiple cell types naturally migrate to the site of inflammation to serve a reparative 
function. Drug loaded coatings attached to these naturally-homing cells offer a new 
opportunity to target therapies to the inflamed region. However, the coverage of the entire 
surface of transporter cells with biomaterials would interfere with the migration and 
cellular activities of transporter cells throughout the body. Cellular patches were originally 
proposed by Rubner’s group [37, 39] to partially cover the migratory cell with a surface 
anchored therapeutic material. In this strategy, polyelectrolyte multilayer (PEM) patches 
containing a magnetic nanoparticle payload were adhered onto the lymphocyte surface. 
These T cells were nearly 100% viable following patch modification and retained their 
migratory capacity with the magnetic PEM patch. This innovative idea of partial surface 
modification is appropriate to allow either T cell interactions involved in immunological 
responses or drug carrying potential for cell-based drug delivery. 
Additional studies in the Mitragotri lab [38] found that PEM-modified multilayer 
patches on the surface of mouse macrophages had no adverse effects on cell viability, 
migration, or phagocytic activity towards polystyrene spheres. Optimization of PEM patch 
size, modulus, and shape enabled prolonged patch attachment on the macrophage surface 
without internalization. In vitro controlled loading of FITC-BSA from polymeric patches 
supports the feasibility of drug delivery with patch coated cells. Patch-coated and uncoated 
monocytes both undergo stimulation-induced differentiation into macrophages. The 
targeting of coated monocytes to inflamed skin and lung tissues was supported in mouse 
models [65]. Higher accumulation of patch-coated monocytes in inflamed tissue over the 
patch alone, illustrated that coated monocytes retained their ability to penetrate across 
barriers to target regions of inflammation. 
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2.3 Coating designed for cancer therapy 
The irregular vessel organization, low oxygen supply, and high interstitial fluid 
pressure of large tumors impedes the delivery of drugs into large malignant tissues. 
Currently, the majority of tumor-targeting approaches use liposomes, micro- or 
nanoparticles, and polymers. However, their insufficient penetration into deep tumor 
tissues and rapid clearance limits therapeutic efficacy. The use of tumoritropic cells as 
drug carriers is a promising new approach to deeply penetrate tumor tissues and increase 
drug efficacy [61].  
There are now multiple examples of drug-coated T cells used for tumor-specific 
targeting of a therapy [66, 67]. T cells, B cells, and natural killer cells all have some level 
of tumoritropic capacity [68-71]. These immune cells migrate across capillaries and blood 
vessels to tumor sites by targeting the cytokines released by the cancer microenvironment 
[66, 67]. Irvine et al coated T cells with liposomes loaded with cytokines promoting help 
T cell differentiation, growth, and endurance at tumor sites [72, 73]. The nanoparticle (NP) 
coatings were optimized to minimize any effect on cells’ tumoritropic migration in vitro 
and in vivo. Later, this team also studied the cell-based delivery of phosphatase-
encapsulated lipid nanoparticles to promote T cell expansion through the delivery of T-
cell regulating phosphatases [73]. T cells were coated with these therapeutic NPs and used 
to treat mouse models of human prostate cancer. Mice treated with coated T cells had 
increased T cell expansion, reduced tumor size, and increased animal survival by 60 days 
over unmodified T cell groups.  
Macrophages are also emerging as a useful tool for cell-mediated penetration into 
tumor masses. They effectively carry drug-encapsulated liposomes into tumors for 
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simultaneous imaging and therapeutic delivery [74]. After surface modification of 
doxorubicin (DOX)-loaded liposomes, these drug-loaded macrophages accumulated at the 
tumor site of an A549 xenograft tumor in a mouse model. 24 h after injection, 
accumulation of DOX was significantly higher in mice treated with of liposome-DOX-
loaded macrophages when compared to PBS, macrophage, DOX and liposome-DOX-
injected controls. The weekly intravenous injection of coated macrophages also decreased 
the tumor size by around 40% when compared to the DOX control group in the same study. 
Many stem cell populations also naturally target tumor sites. Neural stem cells 
(NSC) are actively studied for the delivery of platinum-based therapies to ovarian tumors 
[75]. NSCs are coated with a nonporous silica that encapsulates platinum-based drugs and 
has minimal NSC toxicity. These platinum-loaded particles persisted deep inside in solid 
tumor masses 24 h following intraperitoneal injection into an ovarian cancer mouse model. 
These findings support NSCs as an alternative cell carrier for drug loaded coatings into the 
core of tumor masses. Finally, hMSCs are promising for the delivery of nanoparticle 
payloads into tumor masses [46]. In one study, NP patches were prepared through the 
attachment of NeutrAvidin-coated NPs to partially modify the surface of covalently 
biotinylated hMSCs. Coated MSCs targeted HEPG2 tumor spheroids in vitro, and this 




CHAPTER 3. HYDROGEL PATCHES ON LIVE CELLS THROUGH SURFACE MEDIATED 
POLYMERIZATION 
3.1 Introduction 
Many naturally-occurring cells possess an intrinsic ability to cross biological 
barriers that block conventional drug delivery, and these cells offer a possible mode of 
active transport across the blood brain barrier or into the core of tumor masses. While 
many technologies exist to form complete, nanoparticle loaded coatings on cells, a 
complete coating on the cell surface would disrupt the interaction of cells with their 
environments. To address this issue, cell surface patches that partially cover cell surfaces 
might provide a superior approach for cell mediated therapeutic delivery. In this chapter, 
the goal of this study is to establish a simplified approach to produce polymeric patches of 
arbitrary shapes on a live cell via surface-mediated photopolymerization. Cell surfaces 
were nonspecifically labeled with eosin, and PEGDA coatings were directed to specific 
sites using a 530 nm irradiation through a chrome-coated photomask. These coatings may 
entrap drug loaded or imaging particles. The nonspecific formation of PEGDA hydrogel 
coatings increased with irradiation time, light intensity, and initiating species. 40 mW/cm2 
irradiation for 5 min delivered high-resolution patterns on the surface of A549 cells, and 
these cells remained viable for 48 h post-patterning with fluorescent nanoparticle loaded 
coatings. This work first demonstrated the feasibility to photo-pattern polymer patches 
directly onto the surface of cells. The work presented in this chapter has been published in 
the following peer-reviewed journal paper:   
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Pei-Jung Wu , Jacob L. Lilly, Roberto Arreaza, and Brad J. Berron*. Hydrogel 
Patches on Live Cells through Surface-Mediated Polymerization. 
Langmuir, 2017, 33 (27), pp 6778–6784 
Reprinted with permission from Hydrogel Patches on Live Cells through Surface-
Mediated Polymerization, Copyright 2017, American Chemical Society. 
3.2 Background 
Targeted delivery seeks to minimize off target effects by localizing the therapeutic 
agent to the site of intended action [76, 77]. Much of the prior work focuses on modifying 
a therapeutic particle’s surface chemistry, targeting ligands, shape, and size [78-80].  
Recently, groups have begun loading a therapeutic cargo on the surface of a cell for a 
targeted effect [39, 81]. For example, stem cell-binding silica nanoparticles have been 
utilized for delivering doxorubicin to glioma tumor cells [78]. These cell carriers have also 
delivered encapsulated drugs through the blood-brain barrier and poorly accessible tumor 
tissues [46, 65] . A significant obstacle in these approaches is the adhesion of drugs to the 
surface of the transporter cell while not precluding the cell-directed transport throughout 
the body or interfering with nutrient transportation through the cell membrane [25, 37]. A 
coating that only covers part of a cell’s surface would be capable of drug delivery while 
still allowing the cells to interact normally with the body. Swiston and Rubner attached 
polyelectrolyte multilayer patches on lymphocytes without altering their survival, 
proliferation rate, and normal cell functions [37]. This is the first evidence that cellular 
patches can confine a drug cargo to a region of a cell’s surface. Since then, additional 
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applications of cell patches have been explored using stem cells for delivery of drug-loaded 
polymers to tumor tissue [46] or monocytes to deliver payloads to inflamed tissues [65].  
A variety of techniques have been developed to produce drug loaded cellular 
patches. The PEM patches made by Rubner et al. were manufactured as pre-patterned films 
with a top layer conjugated with a cell binding ligand [37]. A similar concept was applied 
by Mitragotri to generate multilayered “backpack” on monocytes composed of poly 
(methacrylic acid), poly (vinyl-pyrrolidone), poly (allylamine hydrochloride) and anionic 
iron oxide magnetic nanoparticles for delivery to inflamed tissues [38, 65]. The production 
of cellular patches through these techniques requires multiple time-consuming steps of 
polymer film formation and conjugation. In an alternative approach, Anderson et al. used 
sulfosuccinimidyl-6-(biotinamido) hexanoate (sulfo-NHS-LC-biotin) to induce global 
biotinylation of cell surface protein on hMSCs, followed by high affinity of biotinylated 
cell surface with NeutrAvidin-labelled polystyrene nanoparticles [46].  A limitation of this 
technique is that they cannot control the size and shape of the patches, potentially 
interfering with robust interactions between the cell and the biological environment.  
Here, we establish photolithographic patterning of a polyethylene glycol diacrylate 
(PEGDA) hydrogels as a simple technique to produce patches on cell surfaces. The cell 
patch approach is based on the eosin mediated photopolymerization of PEGDA, first 
demonstrated on cell surfaces by the Hubbell lab [82]. The irradiation of visible light (530 
nm) on surface immobilized eosin Y in the presence of TEA initiates PEGDA gel formation 
adjacent to the cell surface. While the Hubbell lab loaded high levels of eosin through 
nonspecific eosin absorption, our lab has previously synthesized 100 nm thick, non-
patterned PEGDA films on cells with lower eosin loadings. Low levels of eosin 
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conjugation (1,600 – 54,000 eosin/µm2) are achieved by contacting a streptavidin-eosin 
conjugate with a cell surface specifically labeled with biotinylated antibodies or 
nonspecifically labeled with a biotinylated NHS species [24].  
In this work, we pattern these coatings on a cell for the first time using standard 
photolithographic techniques. We first characterize PEGDA hydrogel formation on a 
microarray of biotinylated proteins on glass. The thickness, specificity, and spatial 
accuracy of PEGDA pattern formation was evaluated at different irradiation times, 
intensities, and mask positions. After pattern gelation trends are established on a glass 
substrate, we then apply nanoparticle loaded patches to A549 cells (adenocarcinomic 
human alveolar basal epithelial cells). As a potential application, the homing of tumor cells 
to pre-existing tumor sites [83, 84] offers an opportunity to direct the transport of drug-
loaded cells to tumors. A549 cells have been frequently used as an invasive immortalized 
cell line for non-small cell lung cancer [85, 86]. The thickness and feature resolution of 
PEGDA patches deposited on the surface of A549 cells was characterized, and the effects 
of PEGDA pattern formation on cell viability were evaluated. In all, this study investigates 
the key parameters governing the formation of cellular patches through surface-mediated 
PEGDA photolithography. When compared to existing patch strategies, the simplicity of 
this approach decreases the aggregate time and complexity for cellular patch production.  
3.3 Experimental section 
3.3.1 Materials 
Epoxy functionalized slides were obtained from CEL Associates. Bovine serum 
albumin (BSA), eosin-5-isothiocyanate, phosphate-buffered saline tablets, 
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triethanolamine, PEG diacrylate 575, 1-vinyl-2-pyrrolidinone and Whatman chip-clip 
were obtained from Sigma Aldrich (St Louis, MO). Poly (ethylene glycol) diacrylate 8000 
was purchased from Alfa Aesar. Ethyl alcohol (200 proof) was purchased from Pharmco-
aaper. Biotinylated bovine serum albumin, streptavidin, trypsin/EDTA, ethidium 
homodimer-1, yellow-green or nile red fluospheres, collagen I rat protein, sulfo-NHS-LC-
biotin, 16% paraformaldehyde aqueous solution and DAPI were purchased from Thermo 
Fisher scientific. LED lamp with 530 nm wavelength (M530L2-C1) and neutral density 
filter (NE260B) were purchased from Thorlabs. Biotin anti-human EpCAM was purchased 
from BioLegend. The photomask used for surface patterning was a chrome-coated glass 
mask purchased from Louisville Photomask. RPMI-1640 cell culture media was purchased 
from Cellgro and supplemented with 10 v/v% fetal bovine serum (FBS, Gibco, Carlsbad, 
CA), 100 U/mL Penicillin, 10 mg/mL Streptomycin (Gibco) prior to use. 
Adenocarcinomic human alveolar basal epithelial cells (A549) were purchased from 
Lonza (Basel, Switzerland). 1X PBS was prepared by dissolving phosphate buffered saline 
tablets in ultrapure water according to the manufacturer protocol. Streptavidin-eosin was 
prepared as described previously[87]. PBSA was prepared by adding 1 mg/mL bovine 
serum albumin to 1X PBS. 
3.3.2 Eosin conjugation of biotin-immobilized microarrays 
Biotinylated microarrays consisted of an epoxide-coated glass substrate, and serial 
dilutions of biotinylated bovine serum albumin (bBSA, from 1000 to 0.105 μg per mL in 
PBS) were printed on array surface by GMS Affymetrix 417TM Arrayer. Each 
concentration of bBSA was duplicated into two spots. After array printing, the slides were 
dried overnight at room temperature and then were stored in a microscope slide storage 
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box until use. For each microarray experiment, the bBSA-printed slide was loaded in 
Whatman Chip-Clip slide holder, and each Chip-Clip array well was blocked with PBSA 
for 45 min to reduce non-specific interaction on unprinted sites. Array wells were then 
incubated in streptavidin-eosin (25 μg/mL in PBS) for 30 min. 
3.3.3 Culture and eosin photo-initiator conjugation of A549 cells 
The A549 cell line was cultured in RPMI-1640 medium containing 10v/v% FBS 
and 1% streptomycin/penicillin at 37oC incubator with 5% CO2. Cells were cultured 
between 80 and 90 % confluency, and trypsinized prior to use with 0.25% trypsin-EDTA 
(Thermo Fisher) in sterile PBS for 5 min. Glass microscope slides (25mm x 75mm) were 
sterilized in a conical tube by immersion in 200 proof ethanol overnight before cell culture. 
After drying and sterilization, slides placed in a 100 mm petri dish were rinsed with 
sterilized PBS twice and incubated with 415 μL collagen I rat protein solution in 20 mL 
PBS at room temperature for 1 h. Approximately 5 million cells were cultured on the 
collagen-covered slides within a cell culture dish. After cell attachment, cells were cultured 
until >90% confluency for polymerization studies. 
A549-cultured slides were gradually lowered in temperature prior to incubations on 
ice. Specifically, slides in culture dishes were incubated in 25 mL fresh cold medium and 
placed at room temperature for 10 min and then on ice for 20 min, washed with ice cold 
PBS and then loaded into a Whatman slide holder. Each cell well on Whatman Chip-Clip 
was rinsed with 400 μL PBS three times. After rinsing, a freshly prepared biotinylation 
solution of 1 mM sulfo-NHS-LC-biotin was added to the cells for 30 min. Biotinylated 
cells were rinsed with cold PBS three times and incubated with 35 μg/mL streptavidin-
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eosin in PBS for 30 min. After photoinitiator conjugation, cell slides were rinsed with PBS 
three times. 
3.3.4 Non-patterned polymerization of PEGDA on biotin-immobilized microarrays 
PEGDA monomer was composed of 25 w/v% PEG diacrylate 575, 21 or 210 mM 
triethanolamine, and 35 mM vinyl pyrrolidinone. Irradiation conditions were 20, 30, or 
40mW/cm2. The thickness of PEGDA hydrogel on microarray system was observed by 
Dektak 6M stylus surface profilometer. The estimation of PEGDA hydrogel thickness by 
fluorophore was performed by the addition of yellow green fluospheres (2.5 v/v%, Life 
Technology) into the PEGDA monomer solution. The fluorescence of yellow green 
fluospheres was obtained by Nikon Eclipse Ti-U microscope with filter set of 470/535 
excitation /emission. Fluorescence intensity was quantified by image analysis using 
ImageJ software. 
3.3.5 Photo-lithographic polymerization of PEGDA hydrogel patches on biotin-
immobilized microarray or adherent live cells 
For PEGDA hydrogel patches formation, bBSA-immobilized epoxy microarray or 
biotinylated A549 cell surface provided binding sites for streptavidin-eosin conjugation. 
For photolithographic polymerization, the slide (microarray or cell slide) was separated 
from the photomask with two 40 μm thick spacers, and this assembly was held together 
with binder clips. The photomask features consisted of 10 μm thick chrome stripes 
separated by 28 μm spaces. For microarray polymerization, a neutral density filter was 
attached under the glass slide to minimize reflection of the light, and the monomer solution 
was a solution of 25 w/v% PEG diacrylate 575, 21 or 210mM triethanolamine, 35 mM 
vinyl pyrollidinone and 2.5v/v% yellow green Fluospheres in deionized water. For patch 
30 
 
polymerization on live A549 cells, the monomer solution contained 10 w/v% PEG 
diacrylate 8000, 21 mM triethanolamine, 35 mM vinyl pyrollidinone and 2.5 v/v% yellow 
green fluospheres in PBS, and the pH was adjusted to 7.4 with the addition of 1.2 molar 
hydrochloride, as needed. Monomer solutions were bubbled with ultrapure nitrogen in the 
dark for 10 min before photopolymerization. For polymerization, the PEGDA monomer 
solution was pipetted into the space between the slide and photomask. The whole 
photomask assembly system was purged with nitrogen for 3 min. The photomask-
assembled slide was then irradiated under visible-light exposure with peak wavelength of 
530 nm with continuous ultra-pure nitrogen purge. The desired light intensity and 
irradiation time period was selected as a parameter for polymerization. After irradiation, 
microarray slides were gently rinsed with deionized water, blown dry with house air, and 
stored in a microscope slide box. Polymerized cell slides were gently removed from the 
photomask assembly, re-loaded into Whatman chip-clip, and rinsed with PBS three times. 
Images of hydrogel patches were obtained by epi-fluorescence microscopy (Nikon Eclipse 
Ti-U). 
3.3.6 Statistical analysis for microarray hydrogel polymerization  
The fluorescence intensity of nanoparticle-loaded hydrogel patterns was 
quantitated through image analysis using the Image J software. For determination of the 
hydrogel pattern accuracy, the normalized sum of squared error and mean peak intensity 
were calculated by a custom Matlab program. The experimental data of fluorescence 
intensity distribution was normalized and were input into a custom Matlab script to fit a 
Gaussian function to the fluorescence data. The midpoint of the Gaussian curve was 
considered the midpoint of the pattern. The mean peak intensity was determined by the 
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mean of the four data points closest to the pattern midpoint. The normalized ideal pattern 
is defined as a 10 µm wide step function with a magnitude equal to 1. The normalized 
pattern data was determined by scaling the fluorescent intensity data to a maximum of 1. 
The normalized sum of the squared error (Normalized SSE) is defined as the squared 
difference between normalized pattern data and normalized ideal pattern. 
3.3.7 Membrane integrity assay after hydrogel patch polymerization on A549 cells 
After polymerization and rinsing, photopatterned cells were incubated in 2 µM 
ethidium homodimer (Life Technologies) diluted in 3 v/v% FBS in PBS for 30 min. Single 
channel images were obtained by epi-fluorescence microscopy (Nikon Eclipse Ti-U) and 
merged by Image J software. 
3.3.8 PEGDA hydrogel formation on fixed A549 cells 
A549 cells were grown to ~90% confluency on sterilized glass microscopy slides. 
Cells were washed 3 times with cold PBS, then fixed with 1% paraformaldehyde for 10 
min, then washed 3 times again with cold PBS. Slides were blocked with 1% BSA in PBS 
for 40 min. Cells were stained with 10 nM DAPI in PBS for 10 minutes and rinsed 3 times 
with PBS. Slides were then immersed in biotin anti-human EpCAM at 1:100 dilution in 
PBS+ 1%BSA for 40 minutes. Slides were rinsed 1 time with PBS+ 1%BSA then 
immersed in PBS+ 1%BSA with 25 µg/mL SA-EITC for 30 minutes. The slides were then 
rinsed 3 times with PBS and clamped to a chromium/glass photomask with a 40 µm spacer. 
A monomer precursor solution was injected into the photomask setup which consisted of 
420 mM PEG-diacrylate (Mn ~575), 210 mM triethanolamine, 35 mM vinyl 
pyrrolidinone, and 0.05 wt% nile red Fluosphere nanoparticles. The entire setup was then 
exposed to 10 mW/cm2 green LED light (Thorlabs) for 10 minutes and rinsed 3 times with 
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DI water. After drying, the slides were imaged with an inverted epifluorescent microscope 
at 20X objective. 
3.4 Results and discussion 
Cellular patch fabrication typically consists of patterned layer-by-layer coating 
fabrication, adhesion onto the cell surface, and release of the assembly from the 
substrate.[37, 46] In this study, we provide a unique approach for the formation of a drug-
loaded polymer patches through direct photopolymerization of a nanoparticle-loaded 
polymer depot on the surface of a live cell. We expect the photo-polymerization of 
hydrogel cellular patch to have the following attributes: (a) patch fabrication in a 
physiologically-compatible environment; (b) direct hydrogel production onto a portion of 
cell membrane without multistep coating prefabrication; (c) highly controllable patch 
geometry fine-tuned by irradiation conditions and photomask features. To create 
geometrically-controlled polymeric film on the cell’s surface, we take advantage of the 
high affinity between biotin and streptavidin to localize eosin on the cell surface. Cell 
surface biotinylation is attained through labeling surface proteins with sulfo-NHS-biotin, 
and the biotinylated cell surface is contacted with streptavidin-eosin to immobilize low 
concentrations of eosin on the surface. A photomask with striped chrome features is placed 
above adherent A549 cells, and the gap between the cells and the photomask is filled with 
a PEGDA monomer solution. The surface-mediated photopolymerization of PEGDA 




3.4.1 Characterization of PEGDA film polymerization parameters 
The fabrication of PEGDA cellular patches requires a careful balance of gelation 
in irradiated regions with soluble macromolecular species in dark regions. The surface-
mediated photopolymerization of PEGDA is controlled by multiple key parameters: the 
wavelength and intensity of light for photoinitiator excitation, irradiation period, 
composition of monomer and co-initiator, and the density of photoinitiators on the cell 
surface. These parameters alter the rate of polymer gelation on the cell membrane. In 
addition to the complex parameters which govern PEGDA film formation, cells have 
irregular geometries which limit our capacity to directly measure PEGDA pattern 
thickness on cells. To better characterize PEGDA film formation for eventual use on live 
cells, we first utilized an epoxy microarray system without a photomask to characterize 
how these same parameters dictate PEGDA film formation. Based on these results, we 
identify target conditions for cellular patch construction. 
Biotinylated bovine serum albumin (bBSA) microarrays were prepared with serial 
biotin concentrations from 0 to 1000 μg/mL bBSA, where these surfaces were made to 
represent the possible biotin concentrations on our target cell surfaces [24]. These 
microarray surfaces were treated with precursor solution (25 w/v% PEGDA575, 21 or 210 
mM TEA, 35 mM VP and 2.5 w/v% yellow-green nanoparticles in deionized water), and 
exposed to green light (530 nm) under different irradiation conditions (20, 30, and 40 
mW/cm2 for 2.5, 5, and 10 min). The profilometric thickness of PEGDA film generated 
based on bBSA concentration gradient was described in Figure 3.2 A With different 
irradiation conditions, PEGDA hydrogels were thickest (250 ± 8 nm) under 10 min, 
40mW/cm2 irradiation using 210 mM TEA (Figure 3.2 B). With the same TEA 
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concentration and irradiation time, lower irradiation intensity (30mW/cm2 and 
20mW/cm2) produced lower peak thickness (182 ± 4 and 177 ± 4 nm, respectively). 
Despite the similar peak thickness at high bBSA, 20mW/cm2 irradiation had consistently 
lower hydrogel thickness with lower bBSA concentration. Furthermore, under 21 mM 
TEA, same irradiation conditions produced lower hydrogel compared to 210 mM TEA 
(Figure 3.2 C). Taken together, these results supported that the thickness of the polymer 
are predictably controlled by all controllable parameters of the initiation system: the 
density of eosin conjugation, the irradiation energy, and the amine coinitiator 
concentration [50, 52, 53]. 
3.4.2 Fluorophore-labeled PEGDA for thickness estimation 
For the measurement of PEGDA photopatterned coatings, our profilometer lacks 
adequate resolution for PEGDA film features that are less than 1 μm wide because of stylus 
tip radius is ~12 μm. To overcome this limitation, we correlated the fluorescence of 
embedded nanoparticles to the thickness of a PEGDA films on large features [24], and we 
used this correlation to determine submicron feature geometries by epifluorescent 
microscopy. We included 2.5 v/v% of yellow-green nanoparticles to become 
nonspecifically embedded into the hydrogel during polymerization. Fluorescence was 
highly proportional to the actual PEGDA film thickness from 20 to 150 nm (Figure 3.2 B). 
This is consistent with our previous report which used fluorescent intensity to estimate of 
hydrogel thickness [24]. Furthermore, the fluorescence of yellow green was sufficient to 
detect polymer thickness below 50 nm, supporting the feasibility of quantifying PEGDA 
pattern height over the relevant thickness scales for surface mediate polymerization of 
PEGDA coatings.  
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3.4.3 Parameters governing the specificity of gelation in irradiated and non-
irradiated regions 
To better describe the relationship between the irradiation parameters and localized 
gelation via surface mediated polymerization, a chrome photomask was used to restrict the 
irradiation to 10 µm stripes on microarrays of biotinylated surfaces (1000 μg/mL). Figure 
3.3 schematically describes the photomask system, and a photograph of the system is 
provided as Figure A.3. The spacers separating the photomask from the microarray were 
40 μm thick for all data shown, while preliminary studies with thicker spacers had lower 
feature resolution (60, 80 and 100 μm, Figure 3.4). Fluorescence microscopy was used to 
observe the spatial distribution of the fluorescence of yellow-green NPs labeled hydrogel 
patches in a 1 mg/mL bBSA printed microarray spot. Both brightfield and fluorescence 
(ex/em 470/535 nm) microscopy confirm that 10 μm green striped hydrogel patterns were 
confined to regions within the photoinitiator-bound array spots (Figure 3.3). The 
localization of polymer stripes to circular regions confirmed the polymerization was driven 
by specific binding of eosin to the microarray spots. 
The intensity of fluorescence in both irradiated and non-irradiated regions of the 
array spot was analyzed by imageJ. The intensity was then converted to an estimated 
thickness based on the fluorescence-thickness relationship curve described in Figure 3.2 
C. The thickness at non-irradiated regions was consistently < 5 nm and was not dependent 
on light intensity and irradiation period (Figure 3.5). To reduce the light reflection at the 
back side of the glass substrate, a neutral density filter was applied to decrease polymer 
formation in non-irradiated regions of array spots (Figure 3.6).  
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For the irradiated region of the array spot and a 2.5 min irradiation period, there 
was extremely low thickness (<5 nm) showing that no observable polymerization occurred 
for intensities up to and including 40 mW/cm2 (Figure 3.7B). For the irradiated regions 
using light intensities of 30 and 40 mW/cm2 with times of 5 or 10 min, the thickness was 
considerably higher (>30 nm). In contrast, when light intensity was lowered to 20 
mW/cm2, almost no polymer film was generated. The polymer thickness increased with 
both light intensity and irradiation time, and these trends are consistent with unpatterned 
coatings (Figure 3.2B). In all, there is a strong relationship between coating thickness and 
irradiation intensity and time within the irradiated area (Figure 3.7B), while the non-
irradiated area is largely independent (Figure 3.5). However, there was lower polymer 
formation under neutral density filter compared to polymerization without the neutral 
density filter (Figure 3.2 and Figure 3.7). The lower thickness is consistent with a lower 
contribution of reflected light to the irradiation regions, creating a compromise between 
improved feature sharpness and overall polymer thickness. In all, these trends support a 
parameter space for successful pattern formation: 5-10 min irradiation at 30-40 mW/cm2.  
3.4.4 Analysis of coating feature edge sharpness 
To quantify the accuracy of the pattern transferred from the photomask to the 
polymer patch, a normalized sum of square error (SSE) was calculated between the 
experimental topography and an ideal step pattern (Figure 3.7A and 3.7B). The SSE of the 
patterned PEGDA film increased with both irradiation intensity and duration (Figure 
3.7C). In general, the polymer features were larger than the ideal dimensions, and this 
excess polymerization is attributed to the diffusion of oligomers and actively polymerizing 
chains into adjacent non-irradiated areas. Our data shows 40 mW/cm2, 5 min of irradiation 
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generated the PEGDA film with over 50 nm thickness, which is sufficient to load 
nanoparticles [54], but also with modest SSE compared to 40 mW/cm2, 10 min or 30 
mW/cm2, 10 min. In all, high irradiation intensities coupled with low exposure times are 
supportive of thick polymer coatings and high feature accuracy.  
3.4.5 Parameters governing PEGDA pattern formation and viability on A549 cells 
To generate PEGDA film on cell surface, A549 cell surfaces were first biotinylated 
with sulfo-NHS-biotin. Then, slides with biotinylated A549 cells were inserted into the 
same apparatus described in Figure 3.3A. To minimize monomer toxicity, we used 
PEGDA 8000 as the monomer unit for cell surface PEGDA hydrogel photopatterning. 
PEGDA monomers with higher molecular weights have shown to generate less stress and 
more biocompatible [88]. A lower concentration of TEA (21 mM) was used for cell surface 
PEGDA hydrogel formation because higher concentrations (210 mM) are toxic to the cells 
[25]. PEGDA hydrogel are successfully patterned onto A549 cells with monomer solution 
25 and 15 w/v% PEGDA 8000 polymerized under 40 mW/cm2 for 5 min, but these 
conditions also correlated with significant amount of cell death in the irradiated region 
where PEGDA polymer was generated (Figure 3.8). 10 w/v% of PEGDA 8000 was 
sufficient to polymerize PEGDA patterns as evidenced by fluorescence signal of yellow 
green nanoparticle loading, but with much lower cell death rate (Figure 3.9). Most 
importantly, A549 cell survival rate was not affected after 48 hours of incubation followed 
by PEGDA patch generation. As such, photopolymerization is capable of generating 
partial polymer coatings onto live cells in a rapid manner. Furthermore, the shape of the 
patch is modified through the selection of an appropriate photomask. Stripes of 10, 20, and 
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40 µm pitch and circles of 5 and 20 µm are easily achieved on cellular substrates (Figure 
3.10). 
3.5 Conclusions 
This study provides a feasible approach to control the shape of PEGDA hydrogel 
films on live cells. Also, in contrast to existing methods, our approach avoids multiple, 
time-consuming fabrication processes required in advance of the patch deposition. Most 
importantly, PEGDA patches formed through photomask-governed photopolymerization 
does not impact the survival of cells, suggesting the potential use of these coatings as 
biologically-guided, drug delivery vehicles. Further investigation is justified to determine 
the effects of these patches on cell biological functions and to conjugate therapeutic 





Figure 3-1.  Schematic description of A549 cell surface patch photopolymerization. 
(A) Cells are cultured on the collagen-coated slide, and cell surface proteins are targeted 
and biotinylated by sulfo-NHS-biotin. (B) Cell surface biotin is conjugated with the 
streptavidin− eosin conjugate. (C) The PEGDA monomer solution is injected into the gap 
between the photomask and cell slides. Formation of PEGDA hydrogel patches is 
photopolymerized in the presence of the photomask, which allows only light passing 
through the restricted irradiation region to trigger photopolymerization. TEA denotes 





Figure 3-2. Epoxy microarray system for characterizing PEGDA hydrogel formation 
via photopolymerization. (A) Arrangement of the bBSA microarray on an epoxy 
microscope slide. Twelve concentrations of bBSA were printed from 1000 to 0 μg/mL, and 
each concentration has two replicates. (B) Relationship between the log bBSA 
concentration and the PEGDA 575 hydrogel thickness under various light intensities, TEA 
concentrations, and irradiation times. Data are given as means ± the standard error of the 
mean (SEM). (C) Relationship between fluorescence and polymer film thickness. Data are 
given as means ± SEM. The fluorescence was contributed by yellow-green nanoparticle 







Figure 3-3. Photopatterned PEGDA hydrogels in a microarray format. (A) Schematic 
diagram of the experimental setup of the photomask covering a biotinylated BSA-printed 
epoxy microarray. (B) Bright field image of patterned PEGDA hydrogels (left) and 
epifluorescent image of patterned PEGDA hydrogels stained with green fluorescent 
particles (right). The photomask had 10 μm wide irradiated regions. The spacer thickness 












Figure 3-4. PEGDA 575 stripe patch polymerized with different thickness of spacers. 
The spacers used for photomask setup are 40, 60, 80 and 100 μm, respectively.  Scale bar 




Figure 3-5. Relationship between fluorescence intensity of PEGDA 575 pattern and 
irradiation period. For fluorescence at irradiated regions, close diamond: 40 mW/cm2; 
close square: 30 mW/cm2, and close circle: 20 mW/cm2) and irradiation period (2.5, 5 and 
10 min). For fluorescence at non-irradiated regions, opened diamond: 40 mW/cm2; opened 






Figure 3-6. PEGDA 575 photopatterned patches on microarray spots with and 





Figure 3-7. Analysis of PEGDA hydrogel formation rate and accuracy. (A) Schematic 
graph from Matlab analysis of the sum of the square error for PEGDA of photopatterning. 
The dark blue dots are input data of normalized pattern fluorescence. The Gaussian fit (red 
curve) was used to fit the data to obtain the midpoint of experimental results. Four data 
points near the center were averaged to determine the normalized fluorescence value of the 
ideal pattern profile. SSE was calculated by the square difference between experimental 
data and ideal pattern value. The light blue line presents the value of SSE for each data 
point. (B) Relationship of PEGDA 575 gel pattern thickness and irradiation period under 
different light intensities. The nanoparticle-loaded PEGDA hydrogel was polymerized 
under various light intensities [(◆) 40, (■) 30, and (●) 20 mW/cm2] for various irradiation 
periods (2.5, 5, and 10 min). The fluorescence of the hydrogel pattern was analyzed by 
imageJ and then converted to polymer thickness according to the relationship between 
fluorescence and polymer film height. (C) Relationship between normalized SSE and 
irradiation period under different light intensities. The normalized SSE of the hydrogel 




Figure 3-8. Cell viability after hydrogel patch formation with 15 and 25 w/v% 
PEGDA8000 loading. After polymerization, cells were immediately stained with ethidium 
homodimer. The red fluorescence showed that large number of cells at irradiated region 
were dying with higher concentration of PEGDA 8000 monomer. 
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Figure 3-9. Cell membrane permeability following hydrogel patch formation. The 
PEGDA 8000 hydrogel patches were polymerized under 40 mW/cm2 for 5 min. The TEA 
concentration was 21 mM. After polymerization, cells were (A) stained with ethidium 
homodimer immediately or incubated in medium at 37 °C with 5% CO2 for (B) 12, (C) 24, 
or (D) 48 h. The green fluorescence resulted from the yellow-green loaded hydrogel 
patches on the surface of adherent A549 cells. The red fluorescence indicates the 
complexation of the ethidium homodimer with cellular DNA in the nucleus of a 






Figure 3-10. Hydrogel patch formation with different photomask geometries. Under 
fixed cell system, nuclei were stained using DAPI, and nile red fluorosphere-loaded 
PEGDA hydrogels were patterned based on different features of photomask: (A) stripe 
shape with width of 10, 20 and 40 µm; scale bar is 100µm; (B) circular shape with 






CHAPTER 4. BIO-INTERACTIVE COATING FOR MSC-BASED MYOCARDIAL INFARCTION 
THERAPY 
4.1 Introduction  
Myocardial infarction (MI) is a global mortal and morbid disorder that can lead to 
a series of cardiac abnormalities, such as reduced left ventricular (LV) ejection fraction, 
abnormal LV volume, cardiomyopathy and scarring formation, or, even worse, other acute 
systemic diseases, such as kidney failure, stroke, or angina. MI occurs when blood clots 
acutely block the coronary artery, resulting in the lack of oxygen and nutrient supply to 
local tissues. The decreased oxygen level chronically present in the cardiac environment 
seriously endangers functional myocardium, negatively affecting their viability and 
contractibility for preserving regular cardiac activities. At present, long-term cardiac 
treatment has only been through passive strategies by either controlling multiple cardiac 
risk factors such as the level of blood glucose, blood pressure and cholesterol to regulate 
cardiac functions, or offering some anti-thrombotic and anti-platelet drugs to prevent blood 
clots. Although these therapeutic methodologies can moderately relieve the burden on the 
heart, they still cannot repair damaged myocardial functions, reduce scarring formation or 
rejuvenate necrotic cardiomyocytes. Therefore, the use of regenerative stem cells has led 
to new generation of regenerative therapy, especially for therapeutic homing to damaged 
tissues.  
While stem cells allow specialized cell differentiation, local adherence of these 
therapeutic cells to a targeted tissue location after transplantation is highly limited due to 
the absence of homing ligand on cell surfaces. Thus, tailoring stem cell membranes with 
specific targeting reagents can provide functional characteristics which actively direct 
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modified cells to the targeted destination. This chapter will first discuss therapeutic roles 
of MSCs through either immunomodulation or differentiation methods in MI therapy. 
Secondly, current surface coating techniques with targeting materials such as antibody or 
ligands will be discussed to localize inflamed or infarcted tissues for MI treatment, 
providing a basic understanding of material selection and targeting parameters to assist 
tissue targeting efficacy. At last, the chapter will also focus on present cell surface coating 
techniques that simultaneously satisfied the need of disease targeting effects and the 
retention of intrinsic therapeutic functions on treated cells.   
4.2 Stem cell-based therapy for myocardial infarction 
Occlusion to cardiac blood flow creates acute ischemia and a persistent hypoxic 
environment. Based on the cardiomyocyte’s inability to self-regenerate and repair, cardiac 
ischemia leads to severe necrosis and a permanent decrease in contractility. While various 
reperfusion efforts showed reduced infarct size and modestly improved vascular 
endothelial functions [89], there is no effective clinical methodology to compensate the 
irreversible loss of cardiomyocytes after MI. As a result, therapies which protect or 
regenerate tissues post MI are of the utmost urgency. 
 Several stem cell therapies are promising for the treatment ischemic heart diseases 
due to their capacity for differentiation, regeneration, and modulation of inflammation. 
Several types of stem cells, such as hematopoietic stem cells [90], skeletal muscle stem 
cells [91, 92], bone marrow cells [93, 94], cardiac stem cells [95]and MSCs [96], have 
been broadly utilized in cardiovascular therapy. The infusion of progenitor cells, bone 
marrow-derived stem cells and MSCs to damaged tissues have been proposed to support 
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normal biological functions of the heart following an ischemic event. Moreover, the 
delivery of therapeutic MSCs effectively improve the contractility and functionality of 
cardiac muscles, encouraging future use of MSCs for protection of heart function.  
4.3 Mechanism of MSC-based cardiac protection 
4.3.1 MSC-induced Immunosuppression effects  
Accumulating evidence supports the use of MSC-based cardiac therapies in an 
immunosuppressive role to protect health myocardial tissue. The introduction of MSCs in 
buffer to an infarcted heart reduces the scar size and increases cardiovascular function over 
the introduction of buffers alone [97, 98]. Excessive immune responses cause persistent 
damage to heart tissues. The biological functions and actions of activated immune cells 
are closely correlated to MSC interactions (Figure 4.1) [99, 100]. Most significantly, MSC-
macrophage communication drives macrophage polarization and function. The 
macrophage secretion of anti-inflammatory cytokine IL-10 is modulated by MSCs to drive 
a phenotypic change of macrophages toward an anti-inflammatory state. This presence of 
anti-inflammatory macrophages is critical, as the addition of MSCs with the complete 
depletion of the macrophage population significantly increased cardiac adverse 
remodeling and mortality in vivo [100]. Taken together, the introduction of MSCs acts as 
an immunosuppressive mediator to defense overresponsive inflammation [101]. 
MSCs modulate many species in the post-MI environment to modulate 
inflammation beyond interaction with macrophages. IFN-γ and other proinflammatory 
cytokines are secreted from activated T cells, and in combination with TNF-α, IL1-α and 
IL-1β, these factors drive MSC-associated immunosuppressive functions [101-103]. 
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Following a T cell-triggered phenotype shift, MSCs secrete multiple biological molecules 
that directly participate in immune cell pathways, including IDO enzyme, HLA-G5, 
iNOS/NO, prostaglandin E2 (PGE2), HGF or IL-6, to alter the state of immune cells, 
including cytotoxic T cells, T regulatory cells, natural killer cells, dendritic cells, monocyte 
or macrophage [101]. Immunocyte activities are also suppressed by MSC through direct 
and indirect pathways [104-106]. Furthermore, the proliferation of CD4 and CD8 T cells 
can be inhibited by nitric oxide [104] or HLA-G5 [107] production, cellular division and 
IL-2 generation from T cells can be delayed by PGE2-stimulated pathway [108], and 
intracellular apoptosis signaling can be processed by secreted IL-6 [109].  
4.3.2 Mechanism of MSC differentiation into cardiac-related cell lineages 
The multipotency of MSC also offers the potential for differentiation into multiple 
cardiac cell lineages. The elevated expression of VEGF and FGF in an infarct environment 
supports MSC reprogramming into several types of vascular-phenotypic cells, including 
endothelial cells (EC) and smooth muscle cells, which are essential and fundamental 
components to structurally and physiologically support vasculature reconstruction [110-
114]. In heart, the abundance of laminin proteins in extracellular matrix could induce 
FOX2 upregulated pathway that promotes the EC marker expression and EC-like tubular 
network formation on MSCs [115].    
MSCs are also inducible into a cardiomyocyte lineage. Specific paracrine growth 
signals will drive MSCs towards a cardiomyocyte-like state [114, 116]. IGF-1 pushes the 
MSC to increase myocardial marker expression through the PI3k/Akt pathway. 
Alternatively, the cardiomyocyte differentiation efficacy of engrafted MSCs can be 
effectively enhanced by reacting bFGF in ischemic environment [116]. Other than growth 
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factors, the exposure of chemical modifier 5-Azacytidine stimulates MSCs’ 
cardiomyogenesis through extracellular signal related kinases (ERK) activation pathway 
[117] from the evidence of increased cell beating actions and ventricular morphology shift 
[118].  
4.3.3 Other protective mechanisms of MSCs 
Several other beneficial mechanisms of action have been proposed to explain the 
therapeutic effects of MSCs in the post-MI myocardium. It has been proposed that MSCs 
inhibit the activties of proteolytic cathepsins that degrade extracellular matrix (ECM) 
during heart remodeling [99, 100]. Additionally, MSCs mediate blood coagulation and 
further clotting-associated heart damage [119-121] through the upregulation of urokinase 
plasminogen activator and plasmin activators to block thrombus formation [120]. Finally, 
MSCs excrete fibrinolytic enzymes to inhibit scar formation by cleaving the fibrin matrix 
formed during cardiac remodeling state [121].  
4.3.4 The role of endothelium as a pathological target in MI 
Endothelium is a defensive interface which plays an essential role in regulating 
vascular functions, such as clot reduction, oxidative species production and inflammation 
stimulation. This protective endothelial cell-aligned layer also serves as a significant 
pathological target of various diseases, such us MI, cancers or other inflammatory-related 
diseases, when multiple biological events simultaneously occurs near vessel regions, 
including recruitment of immune cells, diffusion of excess oxidative stresses and induction 
of thrombosis triggered by serious damages near injured tissues [122].Typically, healthy 
endothelial cells are prominent hallmarks to regulate cardiac metabolism, contractility and 
maintain basic cardiac functions. In MI, persistent ischemic injury in infarct sites, 
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however, occurs with severe necrosis, apoptosis and metabolic dysfunction of cardiac 
cells, initiating destructive degradation processes of intracellular matrix. Continuous 
stimulation and generation of degraded cellular contents as well as reactive oxidative stress 
to adjacent extracellular components induces upregulation of pro-inflammatory 
chemokines that can significantly change endothelium phenotypes. TNF-α is a pro-
inflammatory protein that is highly upregulated after acute ischemia. As TNF-α is released 
into inflamed heart, the binding interaction between endothelial surface receptor TNFR 
and its ligand cytokine TNF-α results in a series of upregulated protein transcription of cell 
adhesion molecules (CAMs) on endothelial surfaces by triggering NF-ĸB-based signaling 
pathway [123, 124]. This inflammatory mediator-induced phenotypic alterations on 
endothelial cells is so called “endothelium activation”.  
With elevated biological marker presence on cell surfaces following MI-induced 
inflammation, this activated, antigen-overexpressed endothelium layer can be recognized 
as a highly adhesive interface to attract circulating immunocytes, such as leukocyte, 
monocyte and neutrophil. When inflammation takes place at a site of injury, inflammatory 
cytokines release recruiting signals for leukocyte surface activation. The cause of activated 
leukocyte extravasation is the conjunction of sequential biomechanical processes near 
vascular endothelium, including slow radial motion (rolling), ligand-receptor capture, 
tethering, firm adhesion and then transendothelial migration (Figure 4.2). The surface 
receptor B2-integrins, LFA-1 and Mac-1, highly expressed on activated leukocytes have 
strong affinity toward corresponding ligands such as selectin glycoproteins, ICAM1 or 
VCAM1 on antigen-elevated endothelial alignment [125, 126]. Once the contact between 
leukocyte surface integrin and endothelial surface CAMs occurs, this ligand-receptor 
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affinity promotes the deceleration of leukocyte flowing speed (rolling) through the 
interface of inflamed microvasculature and then lead to leukocyte adhesion, allowing 
leukocyte penetration through the gap between adjacent endothelial cells for further 
leukocyte infiltration into deep tissue area. By understanding cell recruitment behavior 
through inflammation targeting, we will coat MSC membrane with specific targeting 
materials to assist MSC migration to ischemic heart by mimicking leukocyte adhesion on 
inflamed endothelium. 
4.4 Surface coating techniques for targeting endothelium 
Vessel interfaces where endothelium locates are always bearing shear stress from 
peripherical blood, making endothelial cells difficult to be targeted. Thus, several cell 
surface markers of endothelium containing selectins and CAMs were revealed as primary 
targeting sites to deliver drugs, like antioxidant and anti-thrombotic molecules, to 
endothelium layer [127]. To successfully transport drug carriers to targeted tissues, a 
variety of biomaterials has been surface-coated with specific ligands or antibodies. Early 
research from Steinberg’s lab first established the delivery of immunoconjugate beads for 
cell targeting. The coating of lysosomal-targeted antibody on the surface of polystyrene 
Latex spheres was used to examine the lysosomal-mediated actin differentiation activities 
after macrophage phagocytosis [128]. This IgG-coated bead technique was further 
developed for the surface loading of endothelium-targeted antibodies to target CAM-
overexpressed or activated endothelial cells.  
Multiple studies using anti-ICAM1 coating for endothelium targeting has been 
widely applied in different disease treatment. For example, the anti-ICAM1 coated 
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nanobeads with a payload of lysosomal enzyme, which can metabolize excess lysosomal 
stored in tissues, has been utilized for enzyme replacement therapy of Niemann-Pick 
disease [129, 130]. Compared with non-anti-ICAM1-coated group, significantly decreased 
lysosomal accumulation was observed in endothelial cytoplasm [130] or microvasculature 
[129]after the delivery of anti-ICAM-coated drug vehicles without tissue injury. Another 
example is to coat ICAM1 antibody on the surface of catalyze-loaded latex microbeads to 
protect endothelial cells from H2O2-induced oxidative stress. With the coating of targeting 
antibody and loading of H2O2-degradable enzyme, anti- endothelial cells were successfully 
targeted and able to survive under H2O2 shock after the internalization of catalyze-loaded 
beads [131].  
While multiple studies broadly displayed the use of anti-endothelium beads in 
different disease targeting purposes, key parameters that are responsible for endothelium 
binding has been deeply explored to understand optimized coating design for adhesion 
efficacy improvement. Importantly, Eckmann et al. has indicated that the density of 
surface-coated ICAM1 antibody on polystyrene beads is highly dependent on material 
association with ICAM1-expressed endothelium under shear flow, providing the facts that 
antigen-targeted adhesion property can be precisely tuned by surface coating 
characterization [132].    
4.5 Cell surface coating for targeting endothelium 
Stem cells are known to lack homing ligands that target specific cell surface 
markers present on inflamed tissues. Engineering cell membranes with tissue-targeting 
molecules is a promising strategy to assist the orientation of ligand-deficient stem cells 
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toward the inflamed endothelium. For instance, by modifying cell surface with selectin-
targeted ligand sLex, Karp et al. successfully mediate leucocyte-mimicking MSC rolling 
on in vitro selectin-localized surfaces [133] and in vivo inflammation-promoted tissues 
[45]. They demonstrated two different coating techniques to associate sLex ligands with 
MSCs. The first cell surface coating strategy is achieved by using biotin-streptavidin 
affinity to conjugate biotinylated sLex onto streptavidin/lipid-bound cells. The second 
method demonstrated the anchorage of nanosized polymer- sLex chain onto MSC surfaces. 
For both SLex-coating studies, reduced rolling velocities of sLex-coated cells on P-selectin-
modified surfaces were observed under a flow chamber assay, designed to simulate cell 
movement behavior through inner blood vessel wall [45, 133]. Compared to the uncoated 
cells, in vivo nanosized polymer-sLex-coated MSC rolling was also discovered under a 
dynamic real time microscopy and around 35-fold increased sLex-coated cells were found 
in LPS-induced inflamed ear [45]. Instead of applying a coating of natural cell surface 
ligand, Kong’s group used cell coating technique to apply VCAM1-associated material on 
MSC surfaces. Nanoscale coating of synthetic VCAM-binding peptide (VBP) was 
hydrophobically embedded on MSC membranes to target activated endothelium and 
vasculature. This group used surface plasmon resonance to detect the adhesion efficacy of 
VBP-coated cells or VBP peptides on VCAM-expressed endothelium and VCAM1-
containing surfaces. The hyper branch-structured polyglycerol chain that contains VBP 
was proved to have increased association rate constant and lower dissociation rate constant 
than only polyglycerol-coated cells, indicating the implication of surface-coated VBP is a 
key element to cause cell rolling in lower speed and enhance cell attachment on an 
endothelial layer [134]. 
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The other way to specifically bind activated endothelium is the MSC surface 
coating with artificial antibodies that have high affinity with endothelial surface CAMs 
(Figure 4.3). Palmitated protein-G-(PPG)-associated lipid was hydrophobically 
intercalated on MSCs by In Kap Ko et al., allowing the capture of IgG-type antibodies on 
cell membranes by PPG-guided absorption. To determine if cell surface coating of PPG-
anti-ICAM1 enhances MSC retention, a physiological flow assay showed the significant 
increase of MSC resistance to shear stress on anti-ICAM1-coated groups [135]. In the 
same lab, they also established the first animal study to deliver antibody-modified MSCs 
for in vivo treatment of inflammatory bowel disease (IBD) in which cell surface addressin 
is highly expressed on intestinal endothelial layers as a targeting aim. The goal of this 
study is to examine MSC immunosuppressive effects on inflamed colon tissues and 
mesenteric lymph nodes to inhibit immunoactivities following the targeted delivery of 
antibody-engineered MSCs. It was proved that the increased retention of PPG-MSCs, 
incorporated either VCAM1 or addressin antibody, is able to delay spleenocyte 
proliferation, induce the presence of T regulatory cells, and enhance the survival rate of 
IBD-induced mice [136]. While antibody-PPG incorporation exhibited great endothelium 
targeting efficacy in both in vitro and in vivo studies, this protein-G coating technique that 
only has ability to absorb immunoglobin highly restricts the selection of cell-targeting 
materials that can be incorporated on the cell surfaces.  
4.6 Cell surface coatings for targeting myocardial infarcts 
In addition to inflammation targeting, cell surface coating through other targeting 
aims are also employed in cardiovascular diseases. For instance, magnetic nanoparticles 
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have been widely used in various bioimaging and biomedical applications because of their 
responsive properties under magnetic stimuli. Cheng’s group deposited an FDA-approved 
FHP (Feraheme, heparin and protamine) magnetic nanocomposite for cardiosphere-
derived stem cell (CDC) membrane coating to provide cell targeting and imaging 
potentials [137]. The study showed this cell surface deposition with ferromagnetic 
particles had no change in several cellular activities, such as differentiation, proliferation, 
migration, and no oxidative stress was generated in the FHP-coated CDCs. Besides, this 
iron-contained cell coating could be magnetically regulated in vivo to effectively examine 
the mobility of coated cells under an external magnetic field and caused increased retention 
at the infarcted heart region only with coated cell group. Although FHP cell coating on 
CDC cells was loaded through natural cellular uptake, this strategy might accumulate in 
non-infarcted region and affect long-term intracellular activities due to the lack of cell 
ability to metabolize this uptake materials in the cytoplasm. Additionally, SPIONs 
(superparamagnetic iron oxide nanoparticles) are also a popular nanomedicine applied on 
stem cells because of their imaging, tracking and targeting potentials for MRI or magnetic-
based diagnostic assays. However, significant obstacles exist due to their poor metabolism 
and body clearance, unfavorable release to extracellular environment and long-term 
oxidative stress production [138]. 
Following an ischemic shock, a variety of chemokines were recruited near oxygen-
deficient infarcts and play an important role in regulating anti-apoptosis and angiogenesis 
effects [139]. Importantly, the low oxygen level triggers the production of HIF-1α, 
resulting in the upregulation of a stem cell recruited chemokine, SDF-1 (stromal cell-
derived factor-1) in the infarct site [140]. Thus, to enhance stem cell migration and 
60 
 
recruitment to myocardium infarcts, the presence of SDF-1 under hypoxia condition has 
been considered as a significant target by using the interaction between SDF-1 and its 
receptor CXCR4. The cell modification work from Bull’s lab demonstrated the CXCR4-
conjugated lipid coating on MSC membranes significantly enhance cell migration toward 
SDF-1 containing environment [12]. The migration feature of CXCR4-coated cells is 
highly dependent on the dose of SDF-1. This ligand-incorporation work indicated MSC 
recruitment potentials to hypoxia myocadiac regions by cell membrane engineering.  
Cardiomyocyte necrosis accompanying with myofilament remodeling causes 
substantial release and degradation of proteins, vasculature fragment, proteinases and 
enzymes. Elevated breakdown of damaged cardiac molecules has been clinically identified 
as one of important diagnostic indicators of cardiac dysfunction following MI. During 
ischemia, the release of myosin light chain (MLC), a cleavage form of contractile cardiac 
myosin, can be stimulated by MMP-2-guided proteolysis, leading to huge loss of 
contractility and mobility of cardiac muscles [141, 142]. Importantly, it has been clinically 
found that MLC quickly accumulated and reached peak concentration near injured heart 
several days post MI and is closely related to the size of infarct scarring [143], suggesting 
this ventricular myosin fragment can be a significant targeting marker of MI. Similar to 
previously mentioned antibody incorporation for endothelium targeting, antibody coating 
on stem cells was also utilized to target MLC in damaged heart. A bifunctional antibody 
that has dual targeting abilities was designed by Lee RJ et al. to act on both transporting 
therapeutic cells and targeted cells. To create an antibody hybrid, two distinct antibodies 
(anti-CD45 and anti-MLC) were modified by amine-reacted Traut’s reagent and sulpho 
SMCC, respectively, to present sulfhydryl and maleimide groups on each IgG chain for 
61 
 
dual antibody conjugation [144, 145]. The delivery of bispecific antibody-coated 
hematopoietic stem cells (HSCs) was used to target myosin-exposed cardiac cells, showing 
improved ventricular biofunctions with the increased HSC retention 5 weeks post MI 
[144]. The group using biospecific antibody coating strategy also proved therapeutic 
effects in a Langendorff-perfusion mice heart model. The in vivo intravenous 
administration suggested the ability of antibody-coating to restore biological functions of 
cardiac vasculature and to reduce myocardial degradation and fibrosis formation [145]. 
Unfortunately, this anti-MLC coating methodology might mislead surface-coated MSC 
toward undesired destination, since the increased release of myosin fragment into 
circulating blood serum several days following heart failure [143] makes this pathological 
cardiac maker difficult to be specifically targeted only in the ischemic region. Although 
the incorporation of bispecific antibody has high specificity for dual cell targeting, the 
efficacy of cell surface coating by antibody-antigen recognition can be limited. The 
insufficient and restricted marker density and diversity of cell surface antigen expression 
on different cell types make antibody-based coatings less competitive and less adjustable 









Figure 4-1. Immunomodulation strategies of mesenchymal stem cells. Reprinted with 






Figure 4-2. The mechanism of leukocyte transendothelial migration. Reprinted with 






Figure 4-3. MSC surface coating of ICAM1 antibody for endothelium targeting. 














CHAPTER 5. ICAM1-ADHESIVE MSC FOR ENHANCED CELL RETENTION VIA 
INTRAMYOCARDIAL DELIVERY 
5.1 Introduction 
Intramyocardial delivery is a direct route for placing MSCs into an inflamed heart 
to regulate the local inflammation response. The retention of MSCs at the injection site is 
severely limited by the fluid flows that rapidly wash cells away and minimize their 
capacity to modulate cardiac inflammation. To prevent this loss of MSCs and their 
function, this chapter will focus on the development of an anti-ICAM1 coatings on the 
plasma membrane of MSCs to enhance their adhesion to their inflamed environment. 
Covalently biotinylated MSCs were tethered to biotinylated anti-ICAM1 through an 
intermediate deposition of streptavidin layer with unsaturated biotin binding domains. 
MSC surfaces were modified with ~7,000 biotin/µm2 and ~23 antibodies/ µm2. The 
intramyocardial injection of antibody-coated MSCs offered a 3-fold increase of cell 
retention in the heart over the injection of uncoated MSCs. The mechanism of adhesion 
was supported through analysis of MSC adhesion to activated HUVECs and surfaces of 
purified ICAM1 glass under microfluidic shear flow.  
5.2 Background 
MIs are severe cardiovascular events where the occlusion of the blood supply 
damages local tissues. Without access to oxygen and essential nutrients, cells within the 
infarct zone become necrotic and release waves of cytokines driving local inflammation 
to recruit additional inflammatory cells and alter the phenotype of local cells. The spike in 
inflammation drives the spread of damage to tissue outside the initial infarct site, and this 
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wave of inflammation-driven damage continues to spread out into healthy heart tissue for 
weeks following the initial occlusion. As a result, MI-associated damage is dramatically 
worsened by unchecked inflammation following the initial injury. 
MSCs are potent modulators of inflammation and have been effectively utilized in 
vivo to promote immunomodulatory effects of immunocytes, including CD8 T cell, T 
lymphocyte, natural killer cells, dendritic cells and macrophage [104, 107-109]. 
Additionally, MSCs that are pre-stimulated by macrophage-secreted TNF-α and IFN-γ 
release immunosuppressive factors, such as IDO enzyme [148-150], PGE2 and TSG6 
[151], and these factors drive pro-inflammatory monocytes towards an anti-inflammatory 
M2 state [152, 153]. Beyond their immunomodulatory effects, MSCs are effective at 
driving angiogenesis [154, 155] and multilineage differentiation [156, 157] to further 
promote repair to damaged tissues. Through the cooperative action of these mechanisms 
for MSC action, the introduction of MSCs into the heart has been effective in promoting 
cardiovascular function and limiting the expansion of the scarred tissue following MI [158, 
159].  
Direct MSC injection into the healthy tissue surrounding the infarct concentrates 
these therapeutic cells at the site of injury to promote a localized therapeutic effect [160]. 
Unfortunately, the injected cells are rapidly cleared from the injection site, limiting their 
opportunity to modulate the infarct environment. For most injected cell therapies, the vast 
majority of the injected cells are rapidly lost from the injection site [161-164] owing to the 
injected cells and buffer swelling the tissue. The elastic recovery of the heart tissue drives 
fluid escape from the tissue, and the injected cells are swept away [164]. This pressure 
driven flow is further exacerbated by heart muscle contractions and other tissue dynamics 
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in a pumping heart [165-168]. In MSC therapies for MI, these factors combine to yield as 
little as 0.44% of the injected MSCs remaining in the heart 4 days after injection [169]. 
Since a larger MSC dose carries a greater risk of mortality [170, 171], the maximum 
number of MSCs present in the heart post-MI is fundamentally limited by the retention of 
these cells in the peri-infarct tissue. The loss of cells from the infarct site is a critical 
challenge for the future of MSC-based cardiovascular therapies [164].  
We seek to increase the number of MSCs retained in the peri-infarct tissue through 
engineering of the MSC peripheral membrane. Our strategy is to present artificial ligands 
on the MSC plasma membrane to increase adhesion of the MSC to the peri-infarct tissue. 
The inflammatory response to ischemia drives the secretion of proinflammatory factors 
which alter the endothelium to recruit leukocytes and other immune cells. The inflamed 
endothelium overexpresses CAMs, making these CAM-exposed endothelium sheets 
important pathological targets [122-124]. 
Here, we developed a cell surface coating to present antibodies against ICAM1 to 
adhere to the endothelium of infarcted hearts (Figure 5.1a). Through intramyocardial 
injection, we confirmed that the delivery of antibody-coated MSCs provides 3-fold higher 
retention in infarcted heart tissues when compared to uncoated MSC injection. The 
ICAM1 adhesion mechanism is supported through the increased cell adhesion of coated 
MSCs to activated endothelial cells and ICAM1-coated glass under physiological shears. 
Interestingly, we found that the adhesion of cells was improved with lower concentration 
of our biotinylation reagents. Lower concentration of NHS-ester biotin (0.1mM) retained 
50% of the cells under wall shear stresses of 150 dyne/cm2 while no cells were retained 
with 1.0 mM biotinylation. In all, this straightforward coating design significantly 
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enhances the adhesion of MSCs to an infarcted heart through specific targeting of 
overexpression of endothelial ICAM1 in response to local inflammation. 
5.3 Experimental section 
5.3.1 MSC isolation and culture 
Mouse MSCs isolated from C57BL/6 or C57BL/6-Tg (CAG-
EGFP)131Osb/LeySopJ mice (Jackson Laboratory, BarHarbor, ME). Mice were 
sacrificed, femurs, tibias and hip bones were collected and then flushed with PBS 
supplemented with 10% FBS. MSCs used in this study were of a passage less than 10. 
MSCs were cultured in pre-warmed mouse MesenCultTM basal medium, supplemented 
with MesenCult™ 10X Supplement (STEMCELL Technologies), 10% USDA Approved 
Origin FBS (VWR), 1% 200mM L-glutamine (Gibco) and 1% streptomycin/penicillin 
(Gibco). MesenPureTM (STEMCELL Technologies) was added in MSC medium at 1:1000 
dilution right before cell seeding. MSCs were cultured under hypoxic conditions (less than 
5% O2 supply) for MSC cultivation was needed by introducing ultrapure nitrogen into a 
37ºC humidified incubator, with 5% CO2. For cell collection, cells were rinsed with sterile 
PBS (Corning) and treated with 0.25% trypsin/EDTA (Gibco) for 5 min in 37ºC. Serum-
containing medium was added to neutralize the trypsin. Cells were centrifuged at 300 g 
for 5 min and the supernatant was removed by pipetting. The cell pellet was washed once 
and resuspended in ice-cold DPBS before use. 
5.3.2 Preparation of anti-ICAM1 coated MSCs 
All incubation steps for cell membrane antibody incorporation were processed on 
ice. MSCs were rinsed twice with cold PBS. 0.1 mM or 1.0 mM sulfo-NHS-LC-biotin was 
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prepared in PBS immediately before cell incubation, 2 mL of biotin solution per 106 cells 
is added for 1 h. Cells were then rinsed twice with PBS, and 2 mL of 25 µg/mL streptavidin 
in PBS was added for every million cells for 1 h. The streptavidin coated cells were then 
incubated for 1h in 30, 50, or 100 µg/mL biotinylated monoclonal mouse antibody against 
human ICAM1 (clone IH4, Invitrogen) or 100 µg/mL biotinylated monoclonal rat 
antibody against mouse ICAM1 (clone YN1/1.7.4, Invitrogen) in PBS.  
5.3.3 MTT viability assay 
Metabolic activity detection depending on mitochondrial function was evaluated 
by using MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) reagents 
(M6494, Invitrogen). A 12mM MTT solution was prepared in PBS (5mg/mL). 50,000 cells 
were diluted in 1mL MSC culture medium. 200 μL of cell solution was pipetted into 96 
well plate and then incubated with 20 μL of MTT stock for 4 h at 37 °C. Cell supernatant 
was removed after centrifuge (1 rpm, 5 minutes) and 200 μL of DMSO was added to 
dissolve the reacted product. A plate reader (Biotek, Winooski, VT) was used to examine 
the sample absorbance at 570 nm. The percentage of cell viability was determined by 
normalizing the sample absorbance with the positive control.  
5.3.4 Myocardial infarction surgery and intramyocardial cell transplantation. 
Myocardial infarction was induced by permanent left anterior descending artery 
(LAD) ligation in 8-10 week female C57BL/6 mice under 1-3% isoflurane anesthesia 
using a small animal vaporizer system. Immediately after ligation, the animals were 
randomized to receive 25µL of either PBS, MSCs, or anti-ICAM1 modified MSCs 
(125,000 cells per 25uL injection per mouse) via intramyocardial injection to the peri-




5.3.5 Immunohistochemistry analysis 
The hearts were harvested 3 days after MI and MSC injection. Immediately after 
cervical dislocation, the hearts were perfused with cold PBS with 4% paraformaldehyde 
and fixed for 24 hours prior to embedding in a paraffin block. 4 m thick heart tissue 
sections were used for immunofluorescent analysis of heart for evidence of the GFP+ 
MSCs. Briefly, heart tissue sections were exposed to pH 6.0 antigen retrieval buffer 
(Vector Laboratories, Burlingame CA) following the company protocol. Slides were 
blocked with normal goat serum for 16 hours at 4C and stained with primary rabbit anti-
GFP antibodies (Abcam, Cambridge, United Kingdom) following by incubation with 
Alexa 488 secondary goat anti-rabbit antibodies (Abcam, Cambridge, United Kingdom). 
 
5.3.6 Flow Cytometry 
Single-cell suspensions were prepared from digested cardiac tissue as previous 
described [47]. Briefly, hearts collected 3 days after MI were minced then digested using 
a collagenase B (Roche, Indianapolis, IN) and dispase II (Roche, Indianapolis, IN) solution 
for 30 minutes at 37°C with mixing every 5 minutes. The heart cell suspensions were 
strained using 40 μm strainers (VWR, cat#10199-654) to remove tissue debris and 
undigested tissue. Cells were washed with flow buffer with centrifugation (400×g for 10 
min at 4 °C) and suspended in Flow Buffer. Cells were stained with eFluor 660 conjugated 
anti-GFP antibody (eBioscience, Thermo Fisher Scientific, Waltham MA) and analyzed 
using an LSR II (Becton Dickinson) in the University of Kentucky Flow Cytometry Core. 
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We utilized FlowJo v10 (FlowJo, FlowJo Ashland OR) software to generate dot plots and 
analyze the data.  
5.3.7 Macrophage cytokine secretion assay 
BMDMs (Bone marrow-derived macrophage) were isolated and differentiated 
using previously published protocols [172]. Primary macrophages were derived from bone 
marrow cells and cultured for 7 days in DMEM (with 10% L929 cell-conditioned 
medium, and 10% fetal bovine serum). For co-culturing, 5x105 BMDMs were seeded into 
a twelve-well plate. The next day, 20,000 unmodified MSCs or anti-ICAM1 coated MSCs 
were placed into the twelve-well plate with the BMDMs. Co-culture were incubated for 3, 
hours with or without 100 ng/mL lipopolysaccharide (LPS-B5, Invivogen) and IFN- (20 
ng/ml). 
Conditioned media were obtained from BMDMs alone, co-cultured with BM-MSCs, 
or anti-ICAM1-coated BM-MSCs as described above. The secreted TNF- and IL-10 in 
the conditioned media were evaluated using enzyme-linked immunosorbent assay ELISA 
kits (BD OptEIA™) according to the manufacturer instructions. 
5.3.8 Endothelial cell culture, activation and shear assays 
Human Umbilical Vein Endothelial Cells (HUVEC) (#00191027) was purchased 
from Lonza. HUVEC culture medium was prepared by adding 1% streptomycin/penicillin 
and EGMTM-2 SingleQuotsTM Supplements (CC-4176) into EGMTM-2 Basal Medium 
(CC-3156). The EGMTM-2 SingleQuotsTM Supplements include 2% FBS, 0.2 mL 
hydrocortisone, 2 mL hFGF-B, 0.5 mL VEGF, 0.5 mL IGF-1, 0.5 mL ascorbic acid, 0.5 
mL hEGF, 0.5 mL GA-1000, and 0.5 mL heparin. Cells were cultured in a 37ºC incubator 
with 5% CO2. Cells were rinsed with sterile PBS and detached by TrypLE treatment for 5 
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min at 37ºC.  The trypsin was neutralized with culture medium and centrifuged at 300 g 
for 5 min. The supernatant was removed, and cells were resuspended in pre-warmed 
medium or PBS before use or next passage.  
To create a HUVEC monolayer on glass slides, attachment factor was used to 
enhance HUVEC attachment to the glass. Microscope slides (25mm x 75mm) were placed 
in a 50 mL conical tube and pre-sterilized overnight in 70 vol% ethanol and dried before 
use. Each sterilized slide was loaded into a well (3x8cm) in a 4-well rectangular dishes 
and rinsed twice in PBS. Each slide was incubated with 4 mL 1X attachment factor at 37ºC 
for at least 3 h. Excess solution removed and 1x106 of HUVEC in 4 mL EGMTM-2 medium 
was seeded directly onto each slide. Each HUVEC-seeded slide was used for MSC 
adhesion studies after reaching 95% confluency. 
HUVECs were activated through the addition of 4 mL of 10 ng/mL TNF-α in 
growth factor and serum-suppled EGM-2 medium directly onto a HUVEC-adhered 
microscope slide in a 4 well dish at 37ºC incubator for 5 or 20 h.  
ICAM1 expression on adherent HUVECs was qualitatively labeled with 25 µg/mL 
biotinylated mouse antibodies against human ICAM1 in PBS for 45 min, rinsed twice with 
PBS and stained with 2 µg/mL Alexa647-labeled secondary antibodies against mouse IgG 
(Invitrogen) for 45 min. Cells were rinsed in PBS and imaged in the far-red channel of a 
Nikon Ti-U Epifluorescent microscope. 
In cell-cell adhesion studies, HUVEC cells were stained with calcein red for 
tracking. HUVECs were rinsed with serum-free (SF) EGM-2 medium twice. Calcein-red 
orange powder was dissolved in 63 µL pure DMSO and stored in -20 ºC before use. 
HUVEC slides were incubated with in a 1:1000 dilution of the calcein-red orange stock in 
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SF-EGM-2 for 3 min and rinsed twice with SF-EGM-2. Cell slides were blocked with 5% 
BSA in SF-EGM-2 at least for 1 hour. For the in vitro shear assays of GFP MSCs on 
calcein red stained HUVECs, one milliliter of 0.5x106 cells/mL pipetted onto a slide of 
95% confluent HUVEC cells blocked with BSA. The coculture was incubated for 5min at 
37ºC. Cells were sheared using a rectangular parallel plate flow chamber from Glycotech 
(#31-010) with a 0.01-inch-thick gasket. A vacuum pump was used to seal the device to a 
cell-coated slide immersed in PBS. The flow rate of fluid through the chamber was 
controlled with a syringe pump (NEWERA, #4000-US) and two 60 mL syringes 
withdrawing fluid to pull PBS from a reservoir through the chamber at the indicated flow 
rate for 15 s. The fluorescence images of attached GFP-positive MSCs under different 
shears and the number of retained cells were counted with ImageJ analysis.  
Shear stress acting on the cell was calculated as the wall shear stress under 
Newtonian flow in a rectangular cross section based on the following equation (Q= flow 





5.3.9 Quantitation of cell surface group density  
Covalent biotinylation of cell surface proteins was achieved by treating cells with 
various concentration of sulfo-NHS-LC-biotin (0.025; 0.1; 0.5; 1; 2 mM). Two milliliters 
of sulfo-NHS-LC-biotin solution was used to treat 1x106 cells for 1 hour on ice and rinsed 
with ice-cold DPBS twice. One milliliter of 0.5 µg/mL streptavidin-phycoerythrin (SAPE) 
mixed with extra streptavidin protein (0, 20, 60, 80 or 90 µg/mL) was used to label 1x106 
of biotinylated cells for 1hr on ice. After rinsing with ice-cold PBS twice, the fluorescence 
of PE-labeled cells was analyzed by flow cytometry in FL2 channel. 
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QuantiBRITETM PE was purchased from BD Biosciences is a phycoerythrin (PE) 
fluorescence quantitation kit and includes PE calibration beads of known quantity of PE 
conjugated per bead. Red PE fluorescence was collected in FL2 channel (585/40 nm 
bandpass filter) by flow cytometry. The mean FL2 fluorescence per PE was correlated 
from a linear regression and was used for quantitation of PE fluorophore bound to each 
cell. The number of available biotin groups on each cell event was calculated through PE 
calibration curve (Figure 5.2). 
Activated or naïve HUVECs were trypsinized as before and rinsed twice with PBS. 
100 µL of 2.5 µg/mL biotinylated human ICAM1 antibody in ice-cold PBS was added for 
every 106 HUVECs and incubated for 30 min on ice. After rinsing twice with PBS, cells 
were incubated in 500 µL of 0.5 µg/mL SA-PE in PBS. After PBS rinsing, the fluorescence 
of surface-anchored PE was analyzed through flow cytometry in FL2 channel, and a 
relative measure of ICAM1 per cell was determined using the PE calibration curve (Figure 
5.2).   
After coating with antibody against human ICAM1, coated MSCs were incubated 
with 350 µL of PE-conjugated secondary antibody against mouse for 45 min. The PE 
fluorescence acquired by FL2 channel of flow cytometry was compared with calibration 
PE curve to determine the number of ICAM1 antibody coated on a cell by the assumption 
of 1:1 binding ratio between anti-ICAM1 and secondary antibody.  
5.3.10 Preparation of hICAM1-coated slides 
Human recombinant ICAM1 protein was reconstituted at 250 µg/mL in sterilized 
PBS and stored at 4 ºC before use. The density of hICAM1 protein was estimated by 
specifically fluorescent targeting on hICAM1 molecules coated on protein-reactive glass 
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surfaces. Eleven concentrations of hICAM1 protein (250; 150; 100; 50; 25; 12,5; 6.25; 4; 
2; 1 µg/mL and PBSA negative control) were tested in this study. Epoxide slides were 
placed in a lid-covered petri dish, coated with 30µL of hICAM1 protein solution in a 1cm2 
area for 3hr, and then rinsed twice with 0.1% BSA in PBS. ICAM1-immobilized slides 
were loaded into a Whatman Chip Clip, blocked with 0.1% BSA for 30 min, and washed 
with 1X PBS twice. Each ICAM1-coated area was labeled with 50 µL of 30 µg/mL 
biotinylated human ICAM1 antibody for 1 h and rinsed twice with PBS. Biotinylated 
immobilized sites were fluorescently tagged through the incubation of 70 µL diluted SA-
Cy3 (1:40 in PBS) in each well for 30 min. After rinsing with PBS three times, slides were 
dried in a stream of air and scanned in an Affymetrix 428 Microarray Scanner at 30 dB 
gain in the Cy3 channel. The number of Cy3 molecules were estimated by Cy3 calibration 
curve (Figure 5.3) prepared using a Cy3 calibration slide from Full Moon Biosystems and 
image analysis using ImageJ software. 
5.3.11 In vitro adhesion of anti-ICAM1 coated MSCs on ICAM1-immobilized 
surfaces under shears 
A 1 cm by 1 cm region of an epoxy slide was treated with 30 µL of human ICAM1 
protein in PBS at 6.25 for 3 h at room temperature in a sealed dish. The protein-coated 
slides were blocked with 1 mg/mL BSA in PBS for 30 min. 50 µL of 0.5x106 MSCs were 
added onto the ICAM1-coated surface for 5 or 45 min at room temperature. Cells were 
sheared and counted for 30 s using a rectangular parallel plate flow chamber as described 
above. 
5.4 Results and discussion 
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The direct injection of MSCs into the heart wall has been effective in improving 
the function of hearts post-MI. The effective dose of MSCs present in the heart tissue after 
injection is a critical limitation, and this study tests the hypothesis that the synthetic 
incorporation of antibodies against ICAM1 onto the peripheral membrane of the injected 
MSCs will increase the number of MSCs retained at the site of injection. Our strategy is 
to first biotinylate MSCs through incubation in 1 mM sulfo-NHS-LC-biotin (NHS-biotin), 
then coating the MSC surface through incubation in 25 μg/mL streptavidin, and finally 
using the excess biotin binding sites of streptavidin to bind a biotinylated-antibody against 
mouse ICAM1 (100 μg/mL) (Figure 5.1b). Since this method targets the post-MI 
inflammatory environment, we induced MI in our mice with an established infarct model 
where the left anterior descending coronary artery is sutured. The animals are then injected 
with either 1.25x105 MSCs in PBS or 1.25x105 anti-ICAM1 coated MSCs in PBS. There 
was one injection per heart, 25 μL per injection site, and all injections were into the peri-
infarct heart wall, and the infarct zone was determined through visual tissue discoloration. 
Three days following MI and MSC injection, the mice were sacrificed, and the resident 
heart cells were dispersed and analyzed by flow cytometry (Figure 5.4a). Our utilization 
of GFP-labeled MSCs injected into a non-GFP host allows for simple determination of the 
number of injected cells remaining in the host. The number of the injected MSCs 
remaining in the heart on day 3 were significantly higher (p=0.02) for the MSCs coated 
with antibodies against ICAM1 (16 ± 3.7 cells/mg) than for the unmodified MSCs (4 ± 1.4 
cells/mg, Figure 5.4c). This finding is qualitatively supported through the analysis of tissue 
sections from other animals in the study, where GFP+ cells are more frequent in peri-infarct 
tissue sections from the anti-ICAM1 coated MSCs than the uncoated MSCs (Figure 5.4b). 
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In related studies, inflammation-adhesive cell coatings have also been designed on MSCs 
by incorporating functional ligands that target endothelial antigens [16-20]. Coatings with 
a CAM-specific peptide also allowed MSC to target an inflamed endothelium [134], while 
surface incorporation of an ICAM1 antibody enhanced MSC homing to the site of 
inflammation by MSC adhesion on ICAM1-upregulated endothelium [135]. Finally, 
antibodies against VCAM and addressins have also been used to target inflamed tissues in 
a mouse model of inflammatory bowel disease [136]. In all, our study strongly supports 
for the first time that the ICAM1 coated MSC are retained in the heart wall more than the 
established treatment using unmodified MSCs. 
Therapeutic MSCs play multiples biological roles in regenerating new cardiac 
tissues, regulating extracellular immune responses, secreting angiogenesis-induced 
paracrine factors. Therefore, it is essential that our MSC coating strategy preserves the 
biological functions required for MI therapy. We coated MSCs with anti-ICAM1 through 
1mM ester-biotin treatment and the viability of coated cells is preliminarily supported 
through MTT assays as well as MSC expansion in culture. As compared with uncoated 
cells, the MSC viability is not significantly impacted by the anti-ICAM1 coatings (Figure 
5.5).   
Uncoated MSCs or MSCs coated with anti-ICAM1 were prepared using 0.1 mM or 
1 mM NHS-biotin and seeded onto pre-coated tissue flasks in media. After 30 minute of 
cell culture, all groups exhibited similar numbers of attached MSCs and similar 
morphologies, and these groups were indistinguishable two days after treatment (Figure 
5.6), suggesting the minimal interference on MSC expansion. In addition, the intensity of 
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the GFP signal in the cells is correlated to viability and protein production, and the GFP 
signals were also similar across these groups.  
The immunoregulatory function of MSCs is proposed as a dominant mode of 
cardioprotection post-MI. Near an infarct, ischemia-induced apoptotic and necrotic 
cardiomyocytes secrete pro-inflammatory cytokines which drive macrophages into a pro-
inflammatory phenotype. As demonstrated in vivo and in vitro, the introduction of MSCs 
to pro-inflammatory macrophages will reduce the level of pro-inflammatory factors 
secreted from macrophages. Here we specifically assay the capacity for our anti-ICAM1 
coated MSCs to modulate the inflammatory cytokine secretion through an in vitro 
coculture assay with BMDM macrophages.  
The macrophage was directly contacted with uncoated MSCs, anti-ICAM1 coated 
MSCs or serum alone in LPS/IFN- supplemented medium for 3 h. Under LPS and IFN- 
stimulation, macrophages can be stimulated to M1 phenotypes for  proinflammatory TNF-
α secretion [173]. Either the uncoated or anti-ICAM1 coated MSCs cocultured with 
inflammatory macrophages showed significant decreased TNF-α secretion profile when 
compared to macrophage alone (Figure 5.7a). We also investigated the anti-inflammatory 
factor secretion following MSC-macrophage crosstalk. The level of immunosuppressive 
IL-10 in the conditioned medium exhibited higher concentration in both macrophage-
interacted groups compared with non-MSC-interactive macrophage (Figure 5.7b). Hence, 
we can conclude that the immunosuppression effects of MSCs are not adversely influenced 
by the coating, and the cytokine section from macrophages can be regulated in an 
immunosuppressive manner in a presence of anti-ICAM1 coated MSCs.  
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In addition to the preservation of the innate functions of MSCs, we have the power 
to tune the biotin density on the surface of the cell and the density of antibodies against 
ICAM1 presented on our MSCs. The NHS-biotin molecule non-specifically tethers biotin 
groups to amine groups on the MSC’s peripheral membrane. The biotin labeling was 
determined by pairing accessible biotins with a streptavidin molecule labeled with 
phycoerythrin (PE), and comparing flow cytometric fluorescence of each cell to a 
calibration bead of known PE loading (Figure 5.2). By simply controlling the 
concentration of the NHS-biotin in buffer, up to ~7,000 biotin/µm2 (Figure 5.8a). This 
magnitude compares favorably to our previous reports of loading up to 10,000 
molecules/µm2 using a similar NHS-biotin approach [23]. To confirm that there are not 
inaccuracies in the magnitude of fluorescence value based on energy transfer between 
adjacent molecules [174, 175], we competed out the labeled streptavidin with an unlabeled 
streptavidin and found comparable biotin densities as the undiluted streptavidin-PE 
labeling.  
Antibody density on the MSC surface was estimated using PE-labeled secondary 
antibodies against mouse IgG. For an MSC treated with 1 mM NHS-biotin, incubations in 
30, 50, or 100 µg/mL of biotinylated antibodies against ICAM1 resulted in up to 23 
antibodies/μm2 (Figure 5.8b). While ~1 PE is bound per secondary antibody, each primary 
antibody will be tagged by multiple secondary antibodies [176]. As a result, the actual 
density of anti-ICAM1 groups is likely several fold lower. The biotin density (~7,000 
biotin/µm2) represents an upper limit for number of antibodies loaded onto the MSC 
surface. Given the larger size of the antibody (150kDa) [177] over the streptavidin (53 
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kDa) [178] and inefficiencies of sequential binding, it is reasonable there are order several 
orders of magnitude fewer antibodies than accessible biotin groups. 
Our overall MSC retention hypothesis is based on the expectation that the anti-
ICAM1 coated MSCs adhere strongly to the ICAM1 presented by the inflamed 
endothelium present near the infarct site (Figure 5.1b). To support these proposed 
mechanisms, we contrasted the force of adhesion between anti-ICAM1 coated MSCs and 
an activated endothelial cell with the shear stress exerted by a flowing buffer (Figure 5.9a). 
A near-confluent layer of HUVECs were grown on a microscope slide and were activated 
with a 5 or 20h exposure for TNF-α, and activation was confirmed with fluorescent 
labeling of ICAM1 on HUVECs (Figure 5.10 and 5.11). MSCs were treated with 0.1 mM 
NHS-biotin, streptavidin, and 100 μg/mL biotinylated antibodies against human ICAM1. 
MSCs were allowed to settle on the HUVECs for 5 minutes and then subjected to wall 
shear stress up to 31 dyne/cm2. While greater shear stresses than 31 dyne/cm2 delaminated 
the HUVECs, the chosen shear range captures most of the physiological wall shear stress 
range observed in human arteries (10-70 dyne/cm2), veins (1-10 dyne/cm2) and capillary 
beds (<1 dyne/cm2) [168, 179-181]. For all shear stresses studied, a greater number of the 
anti-ICAM1 coated MSCs were retained on the activated HUVEC cells than unmodified 
MSCs (Figure 5.9b and 5.9c). The retention of anti-ICAM1 coated MSCs was comparable 
with 5 or 20 h exposure to TNF-α. This is attributed to the surface density of ICAM1 on 
the activated HUVECs being in large excess (>500 ICAM1/μm2, Figure 5.11) compared 
to the surface density of the anti-ICAM1 ligands on the MSCs (<23 antibodies/μm2). In 
the absence of TNF-α induced ICAM1 activation, neither the anti-ICAM1 coated MSCs 
or the unmodified MSCs were retained on the HUVEC surface under flow. This is 
81 
 
expected as MSCs do not typically interact with endothelial cells through direct physical 
interactions. The statistically insignificant increase in mean retention of the anti-ICAM1 
coated MSCs over uncoated MSCs on non-activated HUVECs is potentially attributed to 
the low basal expression of ICAM1 on HUVECs is <10 ICAM1/μm2, Figure 5.11). While 
specificity is not required for this application, the antibody-driven mechanism of retention 
is expected to be specific. These in vitro shear studies on activated HUVECs support the 
proposed antibody-antigen mode of retention as the driver for the increased MSC retention 
in vivo. 
To further confirm the proposed mechanism for MSC retention, we evaluated cell 
adhesion to an ICAM1-coated surface under shearing flow (Figure 5.12a). Epoxy coated 
glass slides were incubated in human ICAM1, and the density of ICAM1 on the glass 
surface was determined through fluorescent labeling of ICAM1, and correlation of 
fluorescent intensity to a calibration slide in a microarray scanner. This approach provided 
surface densities of purified protein to 5,000 ICAM1/μm2 (Figure 5.12b), and this range 
encompasses the surface density of ICAM1 on non-activated and activated HUVEC cells 
(Figure 5.11). In particular, we focused on incubations of 6.25 μg ICAM1/mL to give a 
surface density of 2,400 ICAM1/µm2 to replicate the surface density of HUVECs activated 
with 20 h exposure to TNF-α (1,500 ICAM1/µm2). MSCs were added to the ICAM1 
surfaces, incubated for 5 minutes at 37ºC, and subjected to shearing flows. For all groups 
of anti-ICAM1 coated MSCs, the majority of the cells remained adhered for the expected 
physiological range of wall shear stress (<70 dyne/cm2).  Increasing the contact time 
between the MSC and the ICAM1 surfaces to 45 minutes did not have a significant 
increase in the fractional retention of cells, suggesting the adhesion is dominated by rapid 
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binding events, including the expected antibody-antigen interactions. Importantly, the 
fractional retention of anti-ICAM1 coated MSCs on the purified ICAM1 surface compares 
favorably with the fractional retention of for anti-ICAM1 coated MSCs on the activated 
HUVECs. These two systems were run using the same MSC-surface contact times, antigen 
type, and antigen density. The quantitative agreement in MSC retention supports the 
antibody-antigen mode of retention in the HUVEC study, and by extension supports the 
role of antibody coatings in the increase in anti-ICAM1 coated cell retention in vivo. We 
were unable to retain any uncoated MSCs on the ICAM1 coated surface under the most 
minimal shear (Figure 5.13 and 5.14), and this supports our significant differences between 
coated and uncoated cells in vivo, and in the in vitro assay of MSC attachment to activated 
endothelial cells. 
Throughout our in vitro shear assays, MSCs that were biotinylated using 1 mM 
NHS-biotin were retained to a lesser degree than the MSCs that were biotinylated using 
0.1 mM NHS-biotin (Figure 5.9c and 5.12c). This is counter intuitive, given the higher 
ligand density resulting from the 1mM NHS-biotin treatment. Given the necrosis 
associated with >1 mM NHS-biotin [182], we suspect this higher concentration is causing 
damage to the MSCs which we are not able to detect through viability, proliferation, or 
function assays.  It is reasonable to think that excessive conjugation of cell surface proteins 
will have a significant impact on the function of these proteins. The shear assays of coated 
cells on purified surfaces of ICAM1 (Figure 5.12c) still support the antibody-antigen 
mechanism, but the magnitude of the effect is lower with the 1 mM NHS-biotin than for 




Direct injection of cells is commonly thought of as a reasonable method of directly 
controlling the position of cells in vivo. But on its own, direct injection is not capable of 
retaining the majority of these cells at the injection site across multiple clinical applications 
[164, 183-186]. While other studies have demonstrated ICAM1 based retention of cells in 
inflammatory bowel disease [136], this study is the first direct evidence that anti-ICAM 
coatings increase the number MSCs retained in the heart tissue following a heart attack. 
We support the in vivo retention phenomenon with a mechanistic study of the adhesion of 
the cells when subjected to fluidic shears. The anti-ICAM coating significantly increases 
the number of cells retained on activated endothelial cells. To eliminate other cellular 
processes, we further supported this mechanism by coating microscope slides with ICAM1 
protein and demonstrated the enhanced retention of the anti-ICAM1 coated MSCs over 
unmodified MSCs. In all, we connected the design of a cell’s surface can significantly 
increase the number of MSCs remaining in a post-infarct heart by promoting strong 
adhesion between the MSC and ICAM1 presented by the inflamed endothelium. More 
broadly, this study is additional evidence that the intentional engineering of a cell’s 
peripheral membrane is an effective strategy for improving the localization of injected 
cells in the ever-expanding range of emerging cell-based therapies proposed in modern 




Figure 5-1. Scheme of intramyocardial delivery of antibody-coated MSCs. (a) Direct 
intramyocardial injection of antibody-coated MSCs and subsequent interaction of MSCs 
with inflamed endothelium. (b) Incorporation of inflammation-targeted antibody on MSCs 
through biotin-streptavidin affinity.   
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Figure 5-2. Standard calibration curve of PE quantitative beads. 
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Figure 5-4. In vivo Intramyocardial delivery of ICAM1 antibody-coated MSCs in 
infarcted mouse model. (a) Timeline of MI induction, MSC injection and sample 
collection. The coated or uncoated cells were directly injected into peri-infarct area 
immediately after left anterior descending artery ligation. At day 3, the heart sample was 
collected and digested for flow cytometry and immunohistochemistry analysis.  (b) 
Representative immunofluorescent analysis of uncoated and anti-ICAM1 coated GFP-
MSCs retention in infarcted heart tissues. The scale bar is 20 µm. (c) Quantitative retention 
analysis of uncoated MSCs and anti-ICAM1-coated MSCs through flow cytometry. Data 
are presented as mean number of retained MSCs with stand errors (n=4 for uncoated cells 





























Figure 5-6. Cell attachment after anti-ICAM1 coating on GFP+ MSCs. The scale bar 

















Figure 5-8. Quantitation of surface biotin density on biotinylated MSCs. (a) 
Quantitation of biotin groups through competitive binding of SA/SAPE on biotinylated 
cells. The ester-biotin treated cells were stained with four different ratios of SA to SAPE 
(n ≥3). (b) Quantitation of ICAM1 antibodies on the MSC surface with different antibody 
concentrations (30, 50 and 100 µg/mL) through secondary PE labeling (n ≥3). The scale 






Figure 5-9. Cell adhesion on ICAM1-expressed endothelium and cell detachment 
under the presence of shear flow. (a) Schematic diagram of experimental setup of shear-
detached cells on HUVEC monolayer. (b) Fluorescence images of adhesion behavior of 
uncoated or anti-ICAM1 coated MSCs (GFP+) on untreated or TNF-α-treated HUVECs 
(calcein-red staining) under shear flow. The anti-ICAM1 coated cells were treated with 
0.1mM or 1mM ester-biotin, respectively. Cell adhesion behavior was observed before and 
after shear (3dyne/cm2). The scale bar is 100 μm. (c) Relationship between cell retention 





Figure 5-10. Immunostaining of human ICAM1 protein on non-treated or TNF-α 
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Figure 5-11. Quantitative analysis of ICAM1 surface density on non-treated, 5hr 







Figure 5-12. Cell adhesion on ICAM1-modifed glass and cell detachment under the 
presence of shear flow. (a) Schematic diagram of experimental setup of shear-detached 
cells on ICAM1-modifed glass. (b) Relationship of human ICAM1 protein density and 
protein concentration used for epoxide glass modification (n=3). (c) Relationship between 







Figure 5-13. Stationery adhesion of anti-ICAM1 coated MSC on hICAM1-modified 








Figure 5-14. Stationery adhesion of anti-ICAM1 coated or uncoated MSCs on 
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CHAPTER 6. INTRAVENOUS TARGETING OF MSCS TO MODULATE POST-INFARCT 
INFLAMMATION 
6.1 Introduction 
Insufficient MSC homing to targeted inflammation in AMI-induced heart 
represents one of the most critical challenges in regenerative therapy. Targeted cell 
delivery appears to be a promising solution for MSC retention in the heart. Herein, the 
section will demonstrate a cell surface antibody coating on immunosuppressive MSCs for 
inflamed tissue targeting. Initially, by using flow cytometry, the feasibility to coat cells 
with ICAM1 antibody was evaluated by surface group quantitation. The adhesion efficacy 
of coated cells is correlated to antigen presence on ICAM1-modified surfaces. By 
introducing shear flow, I examined the adhesion force present by this antibody-coated 
cells. The optimal adhesion efficacy of coated cells was proposed in this study by 
biotinylating cells with 0.1mM sulfo-NHS-LC-biotin. One day after the cell injection 
through retro-orbital vein, the flow cytometry results showed higher coated MSC 
accumulation in the heart, spleen and lung, as compared to uncoated MSCs. By quantifying 
immune cells such as neutrophil, monocyte, leukocyte and macrophages in the heart 
tissues, the intravenous delivery of anti-ICAM1 coated cells exhibited the dramatically 
reduced post-MI inflammation responses. 
6.2 Background 
Despite significant advances in rapid clinical interventions, acute myocardial 
infarction (AMI) is still plagued by high prevalence, morbidity and mortality. The majority 
of clinical progress centers on the rapid clearance of obstruction and the prevention of 
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restenosis. Critically, the processes responsible for the progressive loss of functional heart 
tissue have already initiated. This initial site of damage kicks off a cascade of inflammation 
that gradually expands the infarct to encompass large sections of the myocardium, 
resulting in tissue fibrosis, ventricular remodeling, heart dilation [187, 188]. Infarct 
expansion and heart’s negligible capacity for regeneration leads to an irreversible loss of 
function and an increased risk of heart failure.  
The prevention of infarct expansion is an exciting path to improve cardiovascular 
function post-AMI. Apoptotic cells release many factors which activate inflammatory cells 
and lead to the abundant production of pro-inflammatory cytokines. This inflammation 
damages nearby healthy tissue and expands the infarct. Mesenchymal stem cells (MSCs) 
are potent modulators of inflammation[189-191]. The inflammatory signal cascade 
triggers the MSCs to release immunosuppressive factors and growth factors [189, 192-
194]. The implantation of MSCs near infarcted tissue has slowed the progression of infarct 
expansion and improved cardiovascular function. Additionally, implanted MSCs have 
some capacity for regeneration through differentiation into endothelial cells, smooth 
muscle cells, and cardiomyocytes [111, 112, 118, 169, 195-201]. In all, the implantation 
of MSCs is promising for protecting the heart from damage post-AMI and repairing 
cardiovascular tissue.  
The most effective mode of MSC implantation post-AMI is the direct injection of 
cells into the heart wall adjacent to the infarct. The precision of an intramyocardial 
injection is unsurpassed for localized MSC delivery, and this strategy has been effective 
in numerous animal studies [91, 202, 203]. Critically, direct injection into the wall of a 
beating heart in humans requires opening of the chest cavity, and the risk associated with 
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this invasive procedure is clinically prohibitive. As a result, most clinical studies sacrifice 
the localization of intramyocardial injection for intravenous (IV) injections with minimal 
targeting of MSCs to the target tissue [160, 161, 204-206]. With IV injections, MSCs 
typically distribute to the lungs and spleen [161, 163, 204]. 
Here, we demonstrate a simple cell surface engineering strategy to home IV 
injected MSCs to an infarct site through inflammation targeting (Figure 6.1). The 
inflammation that drives unfavorable expansion of the infarct actively recruits leucocytes 
through the expression of ICAM1 on endothelial cells. We create MSCs that are coated 
with antibodies against ICAM1 to mimic leucocyte recruitment and support the retention 
of MSCs in the inflamed myocardium. To create a cell with an ICAM1-targeting capacity, 
we covalently biotinylated cell surface proteins with sulfo-NHS-biotin, and then deposited 
a layer of streptavidin to anchor subsequent additions of biotin mouse ICAM1 antibody 
onto the MSC’s peripheral membrane. We hypothesize that the antibody coated cells will 
adhere to ICAM1 and that more IV administered ICAM1 cells when coated with antibodies 
against ICAM1. We test these hypotheses using an established mouse model of AMI, and 
then support the in vivo findings with microfluidic in vitro analysis. The antibody coated 
MSCs are retained on surfaces of mouse ICAM1 and in the infarcted mouse heart more 
than unmodified MSCs. Further, there is a decrease in the number of neutrophils, 
leukocyte, macrophage and monocytes in the infarcted hearts when antibody coated cells 
were administered over unmodified MSCs. While targeting of cells has been applied to 
other inflammatory conditions [135, 136], this work is the first ICAM1 targeting of cells 
to effectively modulate the immune environment of the post-AMI heart.  
6.3 Experimental section 
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6.3.1 MSC isolation and culture 
Mouse mesenchymal stem cells (MSCs) isolated from C57BL/6 or C57BL/6-Tg 
(CAG-EGFP)131Osb/LeySopJ mice (Jackson Laboratory, BarHarbor, ME). After the 
mice were sacrificed, femurs, tibias and hip bones were collected and then flushed with 
PBS supplemented with 10% FBS. MSCs used in this study were of a passage less than 
10. MSCs were cultured in pre-warmed mouse MesenCultTM basal medium, supplemented 
with MesenCult™ 10X Supplement (STEMCELL Technologies), 10% USDA Approved 
Origin FBS (VWR), 1% 200mM L-glutamine (Gibco) and 1% streptomycin/penicillin 
(Gibco). MesenPureTM (STEMCELL Technologies) was added in MSC medium at 1:1000 
dilution right before cell seeding. MSCs were cultured under hypoxic conditions (less than 
5% O2 supply) for MSC cultivation was needed by introducing ultrapure nitrogen into a 
37ºC humidified incubator, with 5% CO2. For cell collection, cells were rinsed with sterile 
DPBS (Corning) and treated with 0.25% trypsin/EDTA (Gibco) for 5 min in 37ºC. Serum-
containing medium was added to neutralize the trypsin. Cells were centrifuged at 300 g 
for 5 min and the supernatant was removed by pipetting. The cell pellet was washed once 
and resuspended in ice-cold phosphate buffered saline (PBS) buffer (Gibco) before use. 
6.3.2 Preparation and surface group quantitation of anti-ICAM1 coated MSCs 
All incubation steps for cell membrane antibody incorporation were processed on 
ice. MSCs were rinsed twice with cold PBS. 0.1 mM or 1 mM sulfo-NHS-LC-biotin was 
prepared in PBS immediately before cell incubation, 2 mL of biotin solution per million 
cells is added for 1 h. Cells were then rinsed twice with PBS, and 2 mL of 25 µg/mL 
streptavidin in PBS was added for every million cells for 1 h. The streptavidin coated cells 
were then incubated for 1h in 30, 50, or 100 µg/mL biotin monoclonal rat antibody against 
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mouse ICAM1 (clone YN1/1.7.4, Invitrogen) in PBS. For intravenous injection, cells were 
treated with 0.1 mM sulfo-NHS-LC-biotin, 25 µg/mL streptavidin and then 100 µg/mL 
anti-ICAM1. 
QuantiBRITETM PE tubes purchased from BD Biosciences is a phycoerythrin (PE) 
fluorescence quantitation kit and includes PE quantitative beads presenting different 
fluorescence intensity levels with the given information of corresponding number of PE 
conjugated per bead. PE fluorescence was collected in the FL2 channel (filtered by 585/40 
bandpass wavelength) by flow cytometry. The calibration curve of mean FL2 fluorescence 
per PE was plotted, and the linear regression equation was used for quantitation of PE 
fluorophore bound to each cell (Figure 6.2).   
MSC-associated antibody was stained by 2 µg/mL of mouse PE-conjugated 
secondary antibody against rat (clone R2B-7C3, Invitrogen). PE fluorescence was 
acquired by FL2 channel in flow cytometry. By assuming the binding ratio of PE, 
secondary antibody and primary ICAM1 antibody is 1:1:1, the number of ICAM1 antibody 
coated on each MSC is estimated by the calibration curve (Figure 6.2).  
6.3.3 Cell attachment and MTT viability assay 
After anti-ICAM1 coating, 0.1x106 coated cells were cultured in a 12.5 cm2 tissue 
culture flask with MSC expansion medium for 2 days. Attachment behavior, cell 
expansion and GFP fluorescence of coated GFP+ MSCs was observed with epifluorescent 
microscopy. 
Metabolic activity detection depending on mitochondrial function was evaluated 
by using MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) reagents 
(M6494, Invitrogen). A 12mM MTT solution was prepared in PBS (5mg/mL). 50,000 cells 
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were diluted in 1mL MSC medium. 200 μL of cell solution was pipetted into 96 well plate 
and incubated with 20 μL of MTT stock for 4 h at 37 °C. Cell supernatant was removed 
after centrifuge (1 rpm, 5 minutes) and 200 μL of DMSO was added to dissolve the reacted 
product. A plate reader (Biotek, Winooski, VT) was used to examine the sample 
absorbance at 570 nm. The percentage of cell viability was determined by normalizing the 
sample absorbance with the positive control.  
6.3.4  Preparation and ICAM1 quantitation of mouse ICAM1-coated slides 
Recombinant mouse ICAM-1/CD54 Fc chimera protein (796-IC, R&D systems) 
was reconstituted at 250 µg/mL in sterilized PBS and stored at 4 ºC before use. The density 
of mouse ICAM1 protein was estimated by specifically fluorescent targeting on mICAM1 
molecules coated on protein-reactive glass surfaces. Twelve concentrations of mICAM1 
protein (100; 50; 25; 12,5; 6.25; 4; 2; 1; 0.5; 0.25; 0.1 µg/mL and PBSA negative control) 
were tested in this study. Epoxide slides were placed in a lid-covered petri dish, coated 
with 30 µL of mICAM1 protein solution in a 1cm2 area for 3 h, and then rinsed twice with 
0.1% BSA in PBS. ICAM1-immobilized slides were loaded into Whatman Chip Clip, 
blocked with 0.1% BSA for 30 min, and washed with 1X PBS twice. Each ICAM1-coated 
area was labeled with 50 µL of 30 µg/mL biotinylated mouse ICAM1 antibody for 1 h and 
rinsed twice with PBS. Biotinylated immobilized sites were fluorescently tagged through 
the incubation of 70 µL diluted SA-Cy3 (1:40 in PBS) in each well for 30 min. After 
rinsing with PBS three times, slides were dried in a stream of air and scanned in an 
Affymetrix 428 Microarray Scanner at 30 dB gain in the Cy3 channel. The number of Cy3 
molecules were estimated by Cy3 calibration curve (Figure 6.3) prepared using a Cy3 
calibration slide from Full Moon Biosystems and image analysis using Image J software. 
105 
 
6.3.5 Laminar flow chamber assay 
A 1 cm by 1 cm region of an epoxy slide was treated with 50 µL of mouse ICAM1 
protein in PBS (0.1; 1; 6.25; 100; 250 µg per mL) for 3h at room temperature in a sealed 
dish. The protein-coated slides were blocked with 1 mg/mL BSA in PBS for 30 min. 50 
µL of 0.5x106 coated or uncoated MSCs were added onto the mICAM1-coated surface for 
45 min at room temperature.  
To assemble the flow chamber system, a parallel laminar flow chamber from 
Glycotech (#31-010) was flipped upside down with a 0.01-inch-thick gasket tightly 
mounted on the chamber bottom. In this microfluidic chamber, tubing is connected to the 
inflow port from a PBS-filled reservoir. The tubing from the outflow port was connected 
to two 60 mL syringes on a two-channel syringe pump (NEWERA, #4000-US). Additional 
tubing was connected to a vacuum pump to secure the device to the sample slide. The 
entire gasket area on the slide was covered with PBS, the sample slide was then gently and 
parallelly covered, to avoid bubble formation in the device. The vacuum pump then 
secured the slide to the microfluidic device. To introduce laminar flow, the syringe pump 
was turned on to pull the liquid into the system at various flow rates. GFP-cells were 
sheared for 30 s, and the number of cells remaining on the slide were counted using 
ImageJ. 
6.3.6 Myocardial infarction surgery and Intravenous MSC delivery 
MI surgery was performed as previously described [47]. Briefly, 8-10-week female 
C57BL/6 mice were anesthetized under 1-3% isoflurane using a small animal vaporizer 
system. MI was induced by permanent left anterior descending artery (LAD) ligation. Two 
hours after MI surgery, mice were randomized to receive 100uL of either PBS, MSCs, or 
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anti-ICAM1 modified MSCs (1x106 cells per injection per mouse) via intravenous 
injection. Pain medications were administrated after surgery for 24-48 hours. 
6.3.7 MSC in heart, spleen and lung and inflammatory cells in infarcted heart 
Single-cell suspensions for flow cytometry analysis were prepared from digested 
cardiac tissue as previous described [47]. Briefly, hearts and lungs collected 1 day after MI 
were minced then digested using a collagenase B (Roche, Indianapolis, IN) and dispase II 
(Roche, Indianapolis, IN) solution for 30 minutes at 37°C with mixing every 5 minutes. 
The cell suspensions in the heart, lung and spleen were strained using 40 μm strainers 
(VWR, cat#10199-654) to remove tissue debris and undigested tissue. Cells were washed 
with flow buffer with centrifugation (400×g for 10 min at 4 °C) and suspended in Flow 
Buffer. Retained GFP+ MSCs were stained with eFluor 660 conjugated anti-GFP antibody 
(eBioscience, Thermo Fisher Scientific, Waltham MA) and analyzed using an LSR II 
(Becton Dickinson) in the University of Kentucky Flow Cytometry Core. For cardiac 
inflammatory cells, antibodies against Ly6G/C (BD Pharmingen), CD45 (Biolegend), 
CD115 (Biolegend), CD11b (Biolegend), and F4/80 (Biolegend) were used to identify 
inflammatory neutrophils, macrophage, leukocyte and monocytes. We utilized FlowJo v10 
(FlowJo, FlowJo Ashland OR) software to generate dot plots and analyze the data. 
6.4 Results and discussion 
IV injection is a simple and minimally invasive route for MSC delivery, but the 
poor recruitment of MSCs to the heart limits the efficacy of IV administration. Our strategy 
to increase the MSC population in the heart is to coat the MSCs with antibodies against 
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vascular inflammation associated markers (ICAM1) and allow these cells to naturally 
home to the ICAM1 upregulation surrounding the infarct.  
Our approach for anti-ICAM1 cell coatings is to use the multivalence of 
streptavidin to connect a biotinylated cell surface to a biotinylated antibody. The cell 
surface is biotinylated with incubation of MSCs in 0.1 mM or 1 mM sulfo-NHS-biotin for 
1 hr. The biotinylated cells are then incubated in 25 μg/mL streptavidin, and then in 
biotinylated antibodies against mouse ICAM1. The number of antibodies on the cell 
surface was estimated by fluorescently tagging the anti-ICAM1 with secondary antibodies 
and relating the measured PE fluorescence to a calibration curve of fluorescence per PE. 
The resulting number of PE per cell are considered an order of magnitude estimate of the 
number of anti-ICAM1 on the cell surface and dividing by a mean cell surface area 
provides an estimate of antibody density in our coatings. We first modified cells with 0.1 
mM or 1 mM NHS-ester biotin, and then examined coating efficiency by using three 
biotinylated anti-ICAM1 concentration (30, 50 and 100 µg/mL) after streptavidin 
deposition. Interestingly, cell coating through 0.1 mM biotinylation had higher anti-
ICAM1 surface density than 1 mM biotin coated cells. The process using 0.1 mM 
biotinylation delivered up to 74 ± 6.38 anti-ICAM1/µm2 when streptavidin coated cells 
are incubated with 100 µg/mL biotinylated antibody (Figure 6.4a). There is a positive trend 
of antibody density with the concentration of the biotinylated antibody between 30 and 
100 µg/mL for both 0.1 mM or 1 mM biotinylated groups (Figure 6.4a), and this trend is 
also supported qualitatively through epifluorescent imaging (Figure 6.4b). 
 These coatings do not have a negative impact on the viability, proliferation, 
attachment to tissue culture polystyrene, morphology, and immunosuppressive function of 
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MSCs. After anti-ICAM1 coating on GFP+ MSCs, the coated and uncoated cells were re-
cultured into medium-contained tissue culture plastics respectively. Under 2 days 
observation, all the cell groups showed no difference on cell attachment, morphology, and 
cell expansion rate. Additionally, the GFP fluorescence remains the same on both coated 
and uncoated cells (Figure 6.5). Moreover, cell viability is the second important indicator 
of normal cellular function. In this study, MTT assay was used to evaluate cell health after 
coating. The coated MSCs were treated with 0.1mM sulfo-NHS-biotin, 25 µg/mL 
streptavidin and 100 µg/mL antibody against mouse ICAM1. As positive control, uncoated 
cells were mixed with mitochondrial reactive reagents for metabolic activity 
determination. After 4 h MTT incubation, the anti-ICAM1 coated cells showed no 
significant influence in cell viability (Figure 6.6), which suggests the feasibility for cells 
to maintain their cellular functions after modification.  
To support the proposed mechanism of targeting through differential adhesion to 
endothelial ICAM1 expression, we quantified adhesion of coated and uncoated MSCs to 
surfaces coated with BSA or mouse ICAM1. To mimic the inflamed endothelial surface, 
we coated epoxy functionalized microscope slides with purified mouse ICAM1 protein. 
The density of ICAM1 that is available for antibody binding was determined with primary 
antibodies against-ICAM1 and Cy3-labeled secondary antibodies (Figure 6.7a). Based on 
this analysis, up to ~9,000 ICAM1 are available for binding. We tested our system with a 
surface marker density as low as 300 ICAM1/ µm2, which is slightly lower than we expect 
the ICAM1 density to be on an activated endothelium. While direct analysis of ICAM1 
density on the inflamed mouse endothelium is not available, surface marker densities on 
endothelial cells rarely reach 104 markers/μm2 [207]. These ICAM1-coated surfaces were 
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contacted with anti-ICAM1 coated MSCs treated with two different biotinylation 
conditions (0.1 mM and 1 mM biotin) and then subjected to laminar shear flow using a 
microfluidic chamber. By anti-ICAM1 coating with 0.1 mM biotinylation, the majority of 
the antibody coated MSCs were retained on the ICAM1 surfaces with antigen density 
higher than 5000 ICAM1/ µm2 for wall shear stresses up to our system limit of 217 
dyne/cm2, while very few cells retained with ~300 ICAM1/ µm2 (Figure 6.7b). On the 
other hand, as compared to 0.1 mM biotin-treated cells, the coated cells through 1 mM 
biotinylation exhibited overall lower retention efficacy (Figure 6.7c), which also agreed 
with the evidence of lower incorporated antibody number on MSC surfaces (Figure 6.4b). 
For our target application, around 90% of anti-ICAM1 coated cells were retained under 
the 15 dyne/cm2 wall shear stress expected in microvessels adjacent to the infarct site 
(Figure 6.7b and 6.7c) [179, 181]. In support of inflammation targeting, negligible 
numbers of these same antibody coated MSCs adhered to control surfaces coated with 
BSA under any shear stress. In literature, unmodified MSCs are not localized to the 
inflammation when injected intravenously [208]. In our in vitro system, the unmodified 
MSCs do not adhere in any measurable amount to the ICAM1-coated surface. In all, the 
in vitro shear data is supportive of a greater number of antibody-coated cell adhering to 
ICAM1-expressing regions than for unmodified cells. Additionally, the antibody coated 
cells are expected to specifically target areas of inflammation through a preferential 
adhesion to regions of ICAM1-expression.  
Based on the higher in vitro retention of anti-ICAM1 coated MSCs through 0.1 mM 
biotinylation than 1 mM biotin coated cells, we selected this optimized coating condition 
for in vivo intravenous injection. Herein, we anticipated the antibody coated cells would 
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specifically target the ICAM1-rich endothelium in the inflamed, post-AMI heart tissue. To 
best mimic clinical implementation of MSC therapies post-AMI, we inject the MSCs into 
the retro-orbital vein of mice that survived for two hours following AMI by ligation of the 
left anterior descending coronary artery. In agreement with clinical injection via a catheter, 
the circulatory pathway for retro-orbital injection provides the heart a first opportunity for 
heart engraftment prior to encountering the lungs or spleen (Figure 6.8a). The mice were 
randomly assigned into three treatment groups (Figure 6.8b): buffer only (n=4; 100 μL 1x 
PBS), unmodified MSCs (n=5; 106 cells in 100 μL 1x PBS), and anti-ICAM1 coated MSCs 
(n=4; 106 cells in 100 μL 1x PBS). Following 24 h, the mice were sacrificed, and each 
heart, lung, and spleen was digested to isolate the cells residing in each organ. The 
quantities of injected MSC were identified based on GFP expression in flow cytometry. 
The number of MSCs retained in the heart had over 3-fold increase for the antibody coated 
cells when compared to the unmodified MSCs (p < 0.05, Figure 6.9a). This supports the 
hypothesis that the antibody coating encourages association of the coated MSC with the 
inflamed endothelium of the heart.  
Interestingly, there was also a significant increase of anti-ICAM1 coated cells (n=3) 
being retained in the lungs and the spleen over unmodified cells (n=4; p < 0.01, Figure 
6.9b and 6.9c). While MSC retention in the lung and spleen have been reported previously 
for unmodified MSCs [167, 209, 210], the increased retention with anti-ICAM1 coatings 
suggests the coating is also enhancing the MSC interactions at these sites. While 
significant inflammation is not expected at the lung and spleen following AMI, the basal 
level of ICAM1 expression on the endothelium may be driving the observed increase in 
off-target MSC retention. Additionally, the low shear stress in these capillary-abundant 
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organs may also attenuate MSC clearance and drive increased cell accumulation with 
minimal increases in adhesion [160].  
As a result, we must conclude the antibody coating drives increased retention of 
MSCs in a nonspecific manner. Importantly, we still observe a significant modulation of 
the peri-infarct immune response with our anti-ICAM1 coated MSCs. Ly6Chi and Cd115 
are the markers positive for inflammatory monocyte while Ly6Chi/Cd115- represent 
neutrophils. The number of Ly6Chi monocytes in the heart was lower for the anti-ICAM1 
MSCs group (n=3) than PBS alone (n=4; P < 0.05, Figure 6.10a) and uncoated cells. 
Similarly, neutrophils are a hallmark of the inflammation, and there were significantly 
fewer neutrophils in the antibody coated MSC group than only buffer and uncoated cell 
injection (n=4; P < 0.05, Figure 6.10b). While there appear to be fewer monocyte, 
macrophages or leukocytes present in the antibody coated MSC group, this difference was 
not conclusive (P>0.05, Figure 6.10c and 6.10d). In all, the antibody coated group offered 
a dramatic reduction of the inflammatory response post-MI.  
6.5 Conclusions 
Systemic IV administration is a more durable MSC delivery method for clinical 
therapy in a minimally invasive manner as compared to direct intramyocardial injection. 
Prior intravenous MSC delivery trials represent the modest cardiac improvement by MSC-
mediated immunomodulation after AMI; however, the rapid clearance of injected cells by 
cardiac contraction and circulatory shear flow highly restrict MSC’s therapeutic benefits 
in an infarct heart. To enhance the persistence of intravenously delivered MSCs in the 
inflamed heart, we demonstrated an ICAM1-targeted coating via biotin-streptavidin 
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bridging. The anti-ICAM1 coating significantly strengthened the cell resistance to 
physiological shears, supporting the feasibility of coated cells to strongly interact with 
post-inflammatory tissues. We support the increase in in vivo MSC homing to the inflamed 
heart compared to uncoated cells after cell delivery into circulatory shear blood. More 
importantly, the significant attenuation in immune cells activities by the delivery of anti-
ICAM1 coated cells exhibited more effective immunosuppressive effects over non-
ICAM1-targeted cell groups. In conclusion, this is a first proof-of-concept study to 
promote post-AMI immunosuppression by transporting ICAM1-adhesive MSCs to the 
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Figure 6-4. Quantitation of incorporated antibody on MSCs. (a) Quantitation of 
ICAM1 antibodies on the MSC surface with different antibody concentrations (30, 50 and 
100 µg/mL) through secondary PE labeling. Cells were coated through 0.1 mM or 1mM 
NHS-ester biotinylation (n ≥3). (b) Fluorescence image of antibody-coated cells through 1 
mM biotinylation with different antibody concentration after secondary PE antibody 




































Figure 6-7. Cell adhesion on mouse ICAM1-modifed glass and cell detachment under 
the presence of shear flow. (a) Relationship of mouse ICAM1 protein density and protein 
concentration used for epoxide glass modification. (b) Cell retention and shear detachment 
of coated cells through 0.1 mM biotinylation under different mouse ICAM1 density (n ≥3). 
(c) Cell retention and shear detachment of coated cells through 1 mM biotinylation under 





Figure 6-8. In vivo Intravenous delivery of anti-ICAM1 coated MSCs in infarcted 
mouse model. (a) The circulatory pathway of intravenously delivered MSCs through retro-
orbital injection. (b)  Timeline of MI induction, MSC injection and sample collection. The 
coated or uncoated cells were intravenously delivered into 2 hours after left anterior 
descending artery ligation. One day after injection, the cell samples in the heart, spleen and 
lung were collected for quantitative analysis through flow cytometry. The images were 




Figure 6-9. MSC accumulation in heart, spleen and lung. (a) Quantitative retention 
analysis of uncoated MSCs and anti-ICAM1-coated MSCs in the heart through flow 
cytometry. (b) Quantitative analysis of uncoated MSCs and anti-ICAM1-coated MSCs in 
the lung. (c) Quantitative analysis of uncoated MSCs and anti-ICAM1-coated MSCs in the 
spleen. Data points are presented as mean cell number, with error bars presenting standard 






Figure 6-10. Immunosuppressive effects in the heart. Cell samples collected from the 
heart tissues after PBS, uncoated MSC or anti-ICAM1 coated MSC injection were 
quantified through flow cytometry by immunostaining with several antibodies, including 
anti-Ly6G/C, anti-CD45, anti-CD115, anti-CD11b and anti-F4/80.  (a) Quantitative 
analysis of Ly6Chi monocytes in the heart. (b) Quantitative retention analysis of 
Ly6Chi/Cd115- neutrophils. (c) Quantitative analysis of Cd11b+ F4/80 cells in the heart. (d) 
Quantitative analysis of Cd45+ cells in the heart. Data points are presented as mean cell 
number, with error bars presenting standard error (n=4 for uncoated cells and PBS 
injection, and n=3 for anti-ICAM1 coated MSCs). 
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CHAPTER 7.  CONCLUSIONS AND FUTURE PERSPECTIVES 
7.1 Conclusions  
Cell surface coating provides non-intrinsic biological properties by incorporating 
functional biomaterials for transporter cells to specifically interact with their environment. 
Based on the diverse molecular structures and unique chemical property of a cell, we are 
allowed to specifically characterize cell surface lipids, proteins, and charged molecules 
through different modification strategies, including lipid intercalation, electrostatic 
deposition, ligand-receptor interaction, antigen-antibody affinity and covalent protein 
crosslinking. In this dissertation, we developed cell surface engineering techniques for cell 
mediated drug delivery or tissue targeting purposes primarily through covalent NHS-ester 
biotin modification.  
Initial work in Chapter 3 proposed a method to generate nanoparticle-loaded 
polymeric patch on living cells through surface-mediated photolithographic 
polymerization. We photopolymerized a nanothin hydrogel pattern by incorporating 
photoinitiator on a biotinylated cell membrane. The fluorescence of fluorophore-
encapsulated PEGDA hydrogel created on a photoinitiator-labeled microarray was used to 
estimate the film height of less than 100 nm on polymerized cells. The biotinylated 
microarray platform that mimicked the polymerization behavior on biotinylated cells 
assists us to precisely control the formation of a 10 µm stripe patch pattern by using a 
photomask with different irradiation parameters. We observed that the 5 min irradiating 
time was an optimized polymerization condition to create a hydrogel patch pattern with the 
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least pattern inaccuracy on living cells without affecting cell viability 2 days after 
polymerization.  
Furthermore, in Chapter 5 and 6 we utilized an inflammation-targeted antibody 
coating on MSCs to promote local cell retention in a post-MI heart through intramyocardial 
or intravenous delivery route. We coated a layer of biotinylated antibody against human or 
mouse ICAM1 protein on a streptavidin-deposited biotinylated cell.  Through direct cell 
injection into peri-infarct area immediately after the MI induction in mice, examination of 
retained cell number in the heart at day 3 from both IHC staining and flow cytometry 
indicated the four-time increased retention of anti-ICAM1 coated cells over uncoated ones 
showing the enhanced inflammation-sensing ability in the heart. The cells coated through 
1mM biotinylation which exhibited ~7000 biotin/µm2 and 23 anti-ICAM1/µm2 indicated 
the available coating condition for cell retention enhancement. In addition, the anti-ICAM1 
coated cells showed significantly increased adhesion force on both inflamed endothelium 
and ICAM1-modified surfaces in a presence of physiological shears (< 30 dyne/cm2) as 
compared to untreated cells. In Chapter 7, the coated cells were intravenously delivered 
through retro-orbital venous in in vivo MI-induced mice model and were then circulated 
into flowing blood to reach the post-MI inflamed regions. In contrast to uncoated cells, we 
observed ~15-fold increase in coated MSC retention in the heart. The overall increase of 
coated MSC accumulation in heart, spleen and lung was also observed, as compared to 
uncoated cells or PBS injection, due to the high ICAM1 sensitivity of coated cells to target 
capillary network in these organs. More importantly, we also noticed the dramatically 
reduced inflammatory activities of multiple immune cells in the heart, including 
inflammatory monocytes, macrophages and neutrophils.  This immunosuppression 
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outcome supports the improvement of cardiac therapeutic effects by the intravenous 
injection of inflammation-recognized MSCs. In conclusion, with our advances in 
integration of different material coatings, our strategy using cell surface covalent 
biotinylation enables the applications ranging from drug delivery to tissue engineering 
potentials. 
7.2 Future perspectives 
7.2.1 Designing a functional polymer coating for drug delivery 
The traditional method to load drug into cell vehicle is through cellular uptake or 
internalization of nanocarriers. However, the dynamic intracellular degradation largely 
limits the drug stability during delivery. Herein, we have demonstrated cell surface 
engineering techniques to introduce a functionalized loading of exogenous biomaterial 
encapsulated in a cell-associated patch film. While our technique using photolithographic 
polymerization is only applicable in the adherent type of transport cells, such as stem cells, 
skeletal fibroblast or macrophage, the use of full surface coating on suspension cells, such 
as neutrophils or lymphocytes, is also a developing field for cell-based drug delivery.  For 
future directions, the polymer coating on living cells can be designed with a desirable 
mechanical or biochemical property in a controllable drug release manner. To create a 
highly crosslinking polymeric payload with stable and durable drug encapsulation efficacy, 
the generation of cell surface polymerized scaffold can be altered by adjusting the reacting 
condition during polymerization, the quantity of reacting chains, the type of monomer 
crosslinker and the addition of functional conjugation on a polymer chain. Considering the 
rapid drug leakage through absorption or physical encapsulation, the particle chemistry of 
127 
 
encapsulated nanocarrier is an important factor to modulate the controlled release profile 
from the cell-coated polymer matrix. For the PEGDA hydrogel coating we generated on 
cells, the small mesh size (less than 10nm) allows complete encapsulation of nanoparticles 
between 10 and 100 nm in size, including liposomes or polystyrene nanoparticles  [54]. 
With drug-loaded patch or polymer coating, we expect the development of a new 
generation of cell-mediated drug delivery that exploits the inherent cellular trafficking 
functions for local targeted therapy.    
7.2.2 Selection of targeting ligand for tissue-targeted specificity 
Our work demonstrated the significant improvement in cell retention and MSC-
guided immunosuppression by intravenously injecting anti-ICAM1 coated MSCs. 
However, the cell entrapment in other organs could interfere the MSC therapeutic 
efficiency to rejuvenate local heart function. Hence, to enhance the cell transportation in 
the local heart, the selection of pathological targets that mainly express or accumulate in 
the infarcted myocardium will be the next exploring topic for ligand or antibody coated 
cells to precisely sense the post-MI injured destination. From our work, the key advantage 
of cell surface biotin modification is its possibility to incorporate various avidin or 
avidin/biotin-associated ligands to fit the applications for different tissue targeting. For 
instance, the membrane incorporation of antibody against tumor-specific receptor could 
assist the hitchhiking of cytotoxic T cells to attack the tumor-residing area. In the future, 
this coating method also provides a non-genetic methodology to apply tumor-recognized 






APPENDIX 1. A549 cell viability and cytotoxicity assay treated with Sulfo-NHS-
LC-biotin 
The A549 cell line was cultured in RPMI-1640 medium containing 10% fetal 
bovine serum (FBS) and 1% streptomycin/penicillin at 37oC incubator. Glass microscope 
slides (25mm x 75mm) were sterilized in a conical tube by ethanol overnight before cell 
culturing. After trypsinization with 5mL typsin for 5 minutes, A549 cells were cultured on 
the microscope slide with a cell density of 1.5 million cells per slide. After cell culture on 
the slides, A549 cells over 80% confluence on microscope slides were placed on ice for 20 
min then washed with ice cold PBS three times and loaded into Whatman Chip-Clip. A 
45mM Sulfo-NHS-LC-biotin (Thermo Scientific) was prepared in dimethyl sulfoxide no 
more than 5 min before incubation Then, cells were treated with 0.5mM, 1mM, 2mM, 
4mM or 8mM of sulfo-NHS-LC-biotin solution diluted from stock solution in ice cold PBS 
for 20 min. After biotinylation, cells were rinsed with cold PBS twice and incubated with 
0.1% calcein (Life Technologies) and 0.2% ethidium (Life Technologies) diluted in PBS+ 
3%v/v FBS for 30 minutes. Images were observed with epi-fluorescence microscope 
(Nikon Eclipse Ti-U) and analyzed by Image J software. Cell viability was calculated by 
the following equation: calcein positive cell number / [calcein labelled cell number + 






Figure A. 1: Calcein/ethidium analysis of sulfo-NHS-LC-biotin treated A549 viability. 
After treatment with 0mM, 0.5mM, 1mM, 2mM, 4mM and 8mM sulfo-NHS-LC-biotin, 
















APPENDIX 2. Microarray of polymerization-based amplification 
Epoxy-functionalized slides were dipped in ethanol overnight before microarray 
printing for sterilization. Twelve serial dilutions of biotinylated bovine serum albumin 
(bBSA, 0.105, 0.262, 0.655, 1.638, 4.096, 10.24, 25.6, 64, 160, 400 and 1000 μg per mL) 
coupled with negative control group (0 μg/mLbBSA) were prepared in PBS 1X. The epoxy 
slides were printed by Affymetrix 417TM Arrayer, with serial bBSA solutions pipetted into 
a 96 well plate. Each concentration of bBSA was duplicated into two spots on the slides. 
After drying overnight, the biotinylated epoxy-functionalized slides were loaded in 
Whatman Chip-Clip, incubated with 400 μl of 0.1% bovine serum albumin diluted in 
phosphate buffered saline (PBSA) in each Chip-Clip array well and covered with foil for 
45 minutes. After each well rinsed with PBSA once, 400μl of SA-EITC (25 μg/mL) 
solution was added into array well in the absence of light for 30 minutes. After the 
conjugation of streptavidin and biotin has finished, each well was rinsed twice with 400 μl 
of PBSA with 5 minutes and once with deionized water. 350 μl of precursor monomer 
solution (259 µl PEGDA 575, 29 μl triethanolamine and 4.5 μl vinyl pyrollidinone 
dissolved in 895 μl deionized water) was pipetted into each well and placed in a clear 
plastic bag which has been purged with ultra-pure N2 for 5 minutes. An LED lamp 
(Thorlabs M530L2-C1) with peak wavelength of 530 nm was adjusted to 1, 5, 10 or 
15mW/cm2 with a radiometer (International Light Technologies (model number 
ILT1400A). Polymerization commenced with the LED irradiation under continuous 
nitrogen flow for 20 minutes. After photopolymerization, the slides were rinsed with 
deionized water and dried overnight. The thickness of polymer film on each array spot was 
measured by Dektak 6M profilometer. The scanning parameters of surface profilometry 
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measurement were set with scan length of 4200 μm for 40 s, stylus force of 1 mg, and 
resolution of 0.350 μm per sample. 
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Figure A. 2. Relationship between bBSA concentration and the thickness of PEGDA 












APPENDIX 3. The setup of photolithographic patch polymerization  
 
Figure A. 3. Photomask assembly for patch polymerization on a biotinylated 
microarray or slides of cultured cells. Reprinted from [182], Copyright 2017, with 














APPENDIX 4. Laminar flow chamber assay  
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